<Version><xmlsource>This XML content was developed by AHRQ's contractor ECRI Institute for the National Guideline Clearinghouse (NGC).</xmlsource><Section SecID="390" OrdBy="100" Name="General"><Field FieldID="161" OrdBy="105" ID="391" Name="Guideline Title" Type="text"><FieldValue Value="&lt;div class=&quot;content_title&quot;&gt;Diagnosis and management of chronic obstructive pulmonary disease (COPD).&lt;/div&gt;" /></Field><Field FieldID="97" OrdBy="110" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Anderson B, Conner K, Dunn C, Kerestes G, Lim K, Myers C, Olson J, Raikar S, Schultz H, Setterlund L. Diagnosis and management of chronic obstructive pulmonary disease (COPD). Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2013 Mar. 68 p.  [81 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="120" OrdBy="115" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Institute for Clinical Systems Improvement (ICSI). Diagnosis and management of chronic obstructive pulmonary disease (COPD). Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2011 Mar. 63 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field Name ="UMLS Concepts"><FieldValue Value="ICD9CM: Chronic airway obstruction, not elsewhere classified  (496); General physical examination  (89.7); Lung transplantation, not otherwise specified  (33.50); Lung volume reduction surgery  (32.22)"/><FieldValue Value="MSH: Adrenal Cortex Hormones ; Adrenergic beta-Agonists ; Advance Directives ; Albuterol ; Amoxicillin-Potassium Clavulanate Combination ; Anti-Bacterial Agents ; Antiviral Agents ; Azithromycin ; Blood Gas Analysis ; Bronchodilator Agents ; Clarithromycin ; Culture Techniques ; Diphtheria-Tetanus-acellular Pertussis Vaccines ; Doxycycline ; Drug Therapy, Combination ; Dry Powder Inhalers ; Ethanolamines ; Exercise ; Expectorants ; Glucocorticoids ; Hospitalization ; Influenza Vaccines ; Ipratropium ; Levalbuterol ; Lung Transplantation ; Medical History Taking ; Metered Dose Inhalers ; Microbial Sensitivity Tests ; Nebulizers and Vaporizers ; Oximetry ; Oxygen Inhalation Therapy ; Patient Education as Topic ; Phosphodiesterase 4 Inhibitors ; Physical Examination ; Pneumococcal Vaccines ; Pneumonectomy ; Prednisone ; Pulmonary Disease, Chronic Obstructive ; Pulmonary Surgical Procedures ; Referral and Consultation ; Respiratory Therapy ; Risk Assessment ; Risk Factors ; Scopolamine Derivatives ; Severity of Illness Index ; Smoking Cessation ; Spirometry ; Steroids ; Theophylline ; Trimethoprim-Sulfamethoxazole Combination "/><FieldValue Value="MTH: Adrenal Cortex Hormones ; Adrenergic beta-Agonists ; Alpha-1-antitrypsin measurement ; Anti-Bacterial Agents ; Antibiotics ; Antiviral Agents ; arformoterol ; Azithromycin ; Blood Gas Analysis ; Brain natriuretic peptide measurement ; Cessation of smoking ; Chronic airway obstruction, NEC in ICD9CM_2014 ; Chronic Obstructive Airway Disease ; Combination Drug Therapy ; Culture Techniques ; Dry Powder Inhaler (device) ; Ethanolamines ; Exercise ; Expectorants ; follow-up ; formoterol ; Glucocorticoids ; Hospitalization ; Influenza virus vaccine ; Lung Transplantation ; Lung Volume Reduction (procedure) ; Metered Dose Inhaler ; Microbial Sensitivity Tests ; mucolytic agents ; Nebulizers ; Oximeter ; Oxygen saturation measurement ; Oxygen Therapy Care ; Patient education (procedure) ; Phosphodiesterase 4 Inhibitors ; physical examination ; Plain chest X-ray ; Pneumococcal vaccine ; Pneumonectomy ; Prednisone ; Pulmonary rehabilitation (procedure) ; Respiratory Therapy ; Risk Assessment ; risk factors ; Spirometer (device) ; Steroids ; Theophylline ; Theophylline Assay ; Trimethoprim-Sulfamethoxazole Combination "/><FieldValue Value="PDQ: amoxicillin-clavulanate potassium ; clarithromycin ; doxycycline ; prednisone ; theophylline ; trimethoprim-sulfamethoxazole "/><FieldValue Value="SNOMEDCT_US: Albuterol  (372897005); Albuterol  (91143003); Alpha-1-antitrypsin measurement  (71530002); Amoxycillin with clavulanate potassium  (89519005); Antibacterial agent  (346325008); Antibacterial agent  (419241000); Antibiotic  (255631004); Antiviral agent  (32249005); Antiviral agent  (372701006); Arformoterol  (423317005); Arformoterol  (423347007); Azithromycin  (387531004); Azithromycin  (96034006); Beta-adrenoceptor agonist  (349920008); Beta-adrenoceptor agonist  (373227004); Blood gas analysis  (167018008); Blood gas analysis  (278297009); Brain natriuretic peptide measurement  (390917008); Bronchodilator  (353866001); Bronchodilator  (372580007); Chronic obstructive pulmonary disease finding  (13645005); Chronic obstructive pulmonary disease finding  (413846005); Clarithromycin  (387487009); Clarithromycin  (83999008); Corticoid preparation  (21568003); Corticoid preparation  (79440004); Diphtheria + tetanus + acellular pertussis vaccine  (429321000124106); Doxycycline  (10504007); Doxycycline  (372478003); Dry powder inhaler  (468395001); Exercise  (183301007); Exercise  (256235009); Exercise  (61686008); Expectorant agent  (372849009); Expectorant agent  (7836006); Formoterol  (386171009); Formoterol  (414289007); Glucocorticoid  (116596006); Glucocorticoid  (35150008); Glucocorticoid  (419933005); Influenza virus vaccine  (396425006); Influenza virus vaccine  (46233009); Inpatient care  (394656005); Ipratropium  (108624006); Ipratropium  (372518007); Levalbuterol  (116090007); Levalbuterol  (398965008); Lung volume reduction surgery  (429609002); Metered dose inhaler  (422059006); Metered dose powder inhaler  (422054001); Microbial culture of sputum  (104173009); Mucolytic agent  (372761008); Mucolytic agent  (49694007); Nebulizer  (334947002); Operation on lung  (387714009); Oxygen saturation measurement  (104847001); Oxygen saturation measurement  (264598005); Oxygen therapy  (57485005); Patient education  (311401005); Phosphodiesterase 4 inhibitor  (703351007); Physical assessment  (302199004); Physical assessment  (5880005); Physical assessment  (81375008); Plain chest X-ray  (399208008); Pneumococcal vaccine  (333598008); Pneumococcal vaccine  (398730001); Prednisone  (10312003); Prednisone  (116602009); Pulmonary rehabilitation  (15081005); Pulse oximetry  (252465000); Pulse oximetry  (708065004); Respiratory therapy  (53950000); Reversibility trial by bronchodilator  (415299008); Risk assessment  (225338004); Risk factor  (80943009); Salmeterol  (108605008); Salmeterol  (372515005); Spirometer  (303501006); Spirometry  (127783003); Steroid  (116566001); Sulfamethoxazole + trimethoprim  (398731002); Sulfamethoxazole + trimethoprim  (703745000); Theophylline  (372810006); Theophylline  (66493003); Theophylline measurement  (360360004); Tiotropium  (407730002); Tiotropium  (409169006); Transplant of lung  (88039007)"/><FieldValue Value="SPN: OXIMETER "/><FieldValue Value="UMD: Analyzers, Laboratory, Blood Gas  (18-617); Inhalers, Aerosol  (12-128); Nebulizers  (12-712); Oximeters  (12-853); Radiographic Systems  (18-429); Radiographic Systems, Digital, Chest  (18-431); Spirometers  (13-674)"/></Field></Section><Section SecID="396" OrdBy="300" Name="Scope"><Field FieldID="140" OrdBy="305" ID="397" Name="Disease/Condition(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Stable chronic obstructive pulmonary disease (COPD) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Acute exacerbations of COPD&lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="103" OrdBy="310" ID="398" Name="Guideline Category" Type="picklist-many"><FieldValue Value="Diagnosis" /><FieldValue Value="Evaluation" /><FieldValue Value="Management" /><FieldValue Value="Treatment" /></Field><Field FieldID="113" OrdBy="315" ID="399" Name="Clinical Specialty" Type="picklist-many"><FieldValue Value="Family Practice" /><FieldValue Value="Internal Medicine" /><FieldValue Value="Pulmonary Medicine" /><FieldValue Value="Thoracic Surgery" /></Field><Field FieldID="114" OrdBy="320" ID="400" Name="Intended Users" Type="picklist-many"><FieldValue Value="Advanced Practice Nurses" /><FieldValue Value="Allied Health Personnel" /><FieldValue Value="Health Care Providers" /><FieldValue Value="Health Plans" /><FieldValue Value="Hospitals" /><FieldValue Value="Managed Care Organizations" /><FieldValue Value="Nurses" /><FieldValue Value="Patients" /><FieldValue Value="Physician Assistants" /><FieldValue Value="Physicians" /><FieldValue Value="Respiratory Care Practitioners" /></Field><Field FieldID="129" OrdBy="325" ID="401" Name="Guideline Objective(s)" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;To improve population health through education, awareness, prevention and evidence-based treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To improve patient care experience and quality of care &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To improve affordability through appropriate diagnosis and treatment that leads to decreasing chronic obstructive pulmonary disease (COPD) per-capita costs &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To increase the quality and use of spirometry testing in the diagnosis of patients with COPD &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To increase the number of patients with COPD who receive information on the options for tobacco cessation and information on the risks of continued smoking &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To increase the percentage of patients with COPD who have appropriate therapy prescribed &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To decrease COPD exacerbation requiring emergency department (ED) evaluation or hospital admission &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;To increase the percentage of patients who have education and management skills with COPD &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="132" OrdBy="330" ID="402" Name="Target Population" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Patients with symptoms of stable chronic obstructive pulmonary disease (COPD) as well as acute exacerbations of COPD in the outpatient setting&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="133" OrdBy="335" ID="403" Name="Interventions and Practices Considered" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Stable Chronic Obstructive Pulmonary Disease (COPD)&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Evaluation/Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assessment of symptoms and/or risk factors (including tobacco use) for COPD &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Medical history and physical examination &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Spirometry (pre-and post-bronchodilator) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Reversibility testing &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Alpha-1-antitrypsin measurement &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Management/Treatment of Stable COPD&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Support for tobacco cessation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pharmacologic approach&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Bronchodilator medications, including albuterol, tiotropium, and salmeterol &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Glucocorticosteroids, inhaled and oral &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Phosphodiesterase 4 inhibitors &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Methods of drug delivery&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Metered-dose inhaler (MDI) with spacer &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Dry powder inhaler (DPI) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Nebulizers &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Theophylline &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Other pharmacologic treatment&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Azithromycin &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Antiviral agents &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Mucolytics &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Oral beta agonists &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Vaccines, including pneumococcal, influenza, and tetanus, diphtheria, pertussis (Tdap) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Non-pharmacologic interventions including pulmonary rehabilitation program and oxygen therapy &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Surgery (lung volume reduction [LVR] for emphysema, bronchoscopic LVR, bullectomy, and lung transplantation) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Ongoing management: follow-up visits, management of comorbidities, referral to pulmonary specialist, discussion regarding advanced health care directives &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;p class=&quot;Note&quot;&gt;&lt;strong&gt;Note&lt;/strong&gt;: The following treatments are discussed but not recommended: regular use of antitussives, leukotriene modifiers, routine use of antibiotics.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Acute Exacerbation of COPD&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Evaluation&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;History and physical examination &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Chest radiograph &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Laboratory tests including arterial blood gas, theophylline level, a sputum culture with susceptibilities, and brain natriuretic peptide (BNP) &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Treatment&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Bronchodilators (e.g., albuterol, levalbuterol) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Systemic steroids &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Antibiotics &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Oxygen saturation/arterial blood gas measurement &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Follow-up &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hospital admission (if no improvement) &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&lt;/div&gt;" /></Field><Field FieldID="134" OrdBy="340" ID="404" Name="Major Outcomes Considered" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Symptom relief &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Exercise tolerance &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Frequency of exacerbations &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Forced expiratory volume in 1 second (FEV&lt;sub&gt;1&lt;/sub&gt;) measures &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Quality of life &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Survival &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Adverse effects of treatment &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Cost-effectiveness &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="405" OrdBy="400" Name="Methodology"><Field FieldID="109" OrdBy="405" ID="406" Name="Methods Used to Collect/Select the Evidence" Type="picklist-many"><FieldValue Value="Searches of Electronic Databases" /></Field><Field FieldID="135" OrdBy="410" ID="407" Name="Description of Methods Used to Collect/Select the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A consistent and defined process is used for literature search and review for the development and revision of Institute for Clinical Systems Improvement (ICSI) guidelines. Literature search terms for the current revision of this document include spirometry, pulmonary rehab, statins, antibiotic treatment and usage, macrolides, gene trial, cardiovascular diseases, metered-dose inhalers, and phosphodiesterase 4 inhibitors &amp;ndash; from June 2010 through September 2012 in PubMed.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="136" OrdBy="415" ID="408" Name="Number of Source Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="115" OrdBy="420" ID="409" Name="Methods Used to Assess the Quality and Strength of the Evidence" Type="picklist-choice"><FieldValue Value="Weighting According to a Rating Scheme (Scheme Given)" /></Field><Field FieldID="149" OrdBy="425" ID="410" Name="Rating Scheme for the Strength of the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Following a review of several evidence rating and recommendation writing systems, the Institute for Clinical System Improvement (ICSI) has made a decision to transition to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Crosswalk between ICSI Evidence Grading System and GRADE&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;hr /&gt;&#xD;&#xA;&lt;table border=&quot;0&quot; cellspacing=&quot;5&quot; cellpadding=&quot;9&quot; summary=&quot;Table: Crosswalk between ICSI Evidence Grading System and Grading of Recommendations Assessment, Development and Evaluation (GRADE)&quot;&gt;&#xD;&#xA;    &lt;thead&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;col&quot;&gt;ICSI GRADE System&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; colspan=&quot;2&quot; scope=&quot;col&quot;&gt;Previous ICSI System&lt;/th&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/thead&gt;&#xD;&#xA;    &lt;tbody&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;&lt;strong&gt;High&lt;/strong&gt;, if no limitation&lt;/td&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class A:&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Randomized, controlled trial&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; rowspan=&quot;2&quot; scope=&quot;row&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class B:&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;[observational]&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Cohort study&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; rowspan=&quot;2&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class C:&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;[observational]&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Non-randomized trial with concurrent or historical controls&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case-control study&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Population-based descriptive study&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;*Low&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Study of sensitivity and specificity of a diagnostic test&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;*Following individual study review, may be elevated to Moderate or High depending upon study design&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class D:&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;[observational]&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Cross-sectional study&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; rowspan=&quot;2&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case series&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Case report&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Meta-analysis&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class M:&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Meta-analysis&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Systematic Review&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Systematic review&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Decision Analysis&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Decision analysis&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Cost-Effectiveness Analysis&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Cost-effectiveness analysis&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class R:&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consensus statement&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Consensus report&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Narrative review&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Guideline&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class R:&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Guideline&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;        &lt;tr&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;            &lt;th valign=&quot;top&quot;&gt;Class X:&lt;/th&gt;&#xD;&#xA;            &lt;td valign=&quot;top&quot;&gt;Medical opinion&lt;/td&gt;&#xD;&#xA;        &lt;/tr&gt;&#xD;&#xA;    &lt;/tbody&gt;&#xD;&#xA;&lt;/table&gt;&#xD;&#xA;&lt;hr /&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Evidence Definitions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;High Quality Evidence&lt;/strong&gt; = Further research is very unlikely to change confidence in the estimate of effect.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Moderate Quality Evidence&lt;/strong&gt; = Further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Low Quality Evidence&lt;/strong&gt; = Further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate or any estimate of effect is very uncertain.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In addition to evidence that is graded and used to formulate recommendations, additional pieces of literature will be used to inform the reader of other topics of interest. This literature is not given an evidence grade and is instead identified as a &lt;strong&gt;Reference&lt;/strong&gt; throughout the document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="116" OrdBy="430" ID="411" Name="Methods Used to Analyze the Evidence" Type="picklist-many"><FieldValue Value="Review of Published Meta-Analyses" /><FieldValue Value="Systematic Review" /></Field><Field FieldID="150" OrdBy="435" ID="412" Name="Description of the Methods Used to Analyze the Evidence" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not stated&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="112" OrdBy="440" ID="413" Name="Methods Used to Formulate the Recommendations" Type="picklist-choice"><FieldValue Value="Expert Consensus" /></Field><Field FieldID="145" OrdBy="445" ID="414" Name="Description of Methods Used to Formulate the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Guideline Development Process&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A work group consisting of 6 to 12 members that includes physicians, nurses, pharmacists, other healthcare professionals relevant to the topic, along with an Institute for Clinical Systems Improvement (ICSI) staff facilitator develops each document. Ordinarily, one of the physicians will be the leader. Most work group members are recruited from ICSI member organizations, but if there is expertise not represented by ICSI members, 1 or 2 members may be recruited from medical groups, hospitals, or other organizations that are not members of ICSI. Patients on occasion are invited to serve on work groups.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The work group will meet for 7 to 8 three-hour meetings to develop the guideline. A literature search and review is performed and the work group members, under the coordination of the ICSI staff facilitator, develop the algorithm and write the annotations and footnotes and literature citations.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Once the final draft copy of the guideline is developed, the guideline goes to the ICSI members for critical review.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Revision Process of Existing Guidelines&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;ICSI scientific documents are revised every 12 to 24 months as indicated by changes in clinical practice and literature. For documents that are revised on a 24-month schedule, ICSI checks with the work group on an annual basis to determine if there have been changes in the literature significant enough to cause the document to be revised earlier or later than scheduled. For yearly reviewed documents, ICSI checks with every work group 6 months before the scheduled revision to determine if there have been changes in the literature significant enough to cause the document to be revised earlier than scheduled.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Literature Search&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;ICSI staff, working with the work group to identify any new pertinent clinical trials, systematic reviews, or regulatory statements and other professional guidelines, conduct a literature search.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;em&gt;Revision&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The work group will meet for 1 to 2 three-hour meetings to review the literature, respond to member organization comments, and revise the document as appropriate.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;A second review by members is indicated if there are changes or additions to the document that would be unfamiliar or unacceptable to member organizations. If a review by members is not needed, the document goes to the appropriate steering committee for approval according to the criteria outlined in the &quot;Description of Method of Guideline Validation&quot; field.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="146" OrdBy="450" ID="415" Name="Rating Scheme for the Strength of the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="148" OrdBy="460" ID="417" Name="Cost Analysis" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The guideline developers reviewed published cost-analyses.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="104" OrdBy="465" ID="418" Name="Method of Guideline Validation" Type="picklist-choice"><FieldValue Value="Internal Peer Review" /></Field><Field FieldID="130" OrdBy="470" ID="419" Name="Description of Method of Guideline Validation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Critical Review Process&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The purpose of critical review is to provide an opportunity for the clinicians in the member groups to review the science behind the recommendations and focus on the content of the guideline. Critical review also provides an opportunity for clinicians in each group to come to consensus on feedback they wish to give the work group and to consider changes necessary across systems in their organization to implement the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All member organizations are expected to respond to critical review guidelines. Critical review of guidelines is a criterion for continued membership within ICSI.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;After the critical review period, the guideline work group reconvenes to review the comments and make changes, as appropriate. The work group prepares a written response to all comments.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Document Approval&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Each document is approved by the Committee for Evidence-Based Practice (CEBP).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The committee will review and approve each guideline/protocol, based on the following criteria:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The aim(s) of the document is clearly and specifically described. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The need for and importance of the document is clearly stated. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The work group included individuals from all relevant professional groups and had the needed expertise. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patient views and preferences were sought and included. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The work group has responded to all feedback and criticisms reasonably. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Potential conflicts of interest were disclosed and do not detract from the quality of the document. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Systematic methods were used to search for the evidence to assure completeness and currency. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Health benefits, side effects, risks and patient preferences have been considered in formulating recommendations. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The link between the recommendation and supporting evidence is clear &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Where the evidence has not been well established, recommendations based on community practice or expert opinion are clearly identified. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Recommendations are specific and unambiguous. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Different options for clinical management are clearly presented. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinical highlights and recommendations are easily identifiable. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Implementation recommendations identify key strategies for &lt;em&gt;health care systems&lt;/em&gt; to support implementation of the document. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The document is supported with practical and useful tools to ease &lt;em&gt;clinician&lt;/em&gt; implementation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Where local resource availability may vary, alternative recommendations are clear. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Suggested measures are clear and useful for quality/process improvement efforts. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Once the document has been approved, it is posted on the ICSI Web site and released to members for use.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="420" OrdBy="500" Name="Recommendations"><Field FieldID="151" OrdBy="505" ID="421" Name="Major Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Note from the National Guideline Clearinghouse (NGC) and the Institute for Clinical Systems Improvement (ICSI)&lt;/strong&gt;: For a description of what has changed since the previous version of this guidance, refer to &lt;a href=&quot;https://www.icsi.org/_asset/4mpxhe/COPDSofC.pdf&quot; title=&quot;ICSI Web site&quot;&gt;Summary of Changes Report -- March 2013&lt;/a&gt;. In addition, ICSI has made a decision to transition to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. This document is in transition to the GRADE methodology. Transition steps incorporating GRADE methodology for this document include the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Priority placed upon available systematic reviews in literature searches. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;All existing Class A (randomized controlled trials [RCTs]) studies have been considered as high quality evidence unless specified differently by a work group member. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;All existing Class B, C and D studies have been considered as low quality evidence unless specified differently by a work group member. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;All existing Class M and R studies are identified by study design versus assigning a quality of evidence (see Crosswalk between ICSI Evidence Grading System and GRADE below in the &quot;Definitions&quot; section). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;All new literature considered by the work group for this revision has been assessed using GRADE methodology. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The recommendations for the diagnosis and management of chronic obstructive pulmonary disease (COPD) are presented in the form of an algorithm with 12 components, accompanied by detailed annotations. An algorithm is provided in the &lt;a href=&quot;https://www.icsi.org/_asset/yw83gh/COPD.pdf&quot; title=&quot;ICSI Web site&quot;&gt;original guideline document&lt;/a&gt; at the ICSI Web site for Chronic Obstructive Pulmonary Disease; clinical highlights and selected annotations (numbered to correspond with the algorithm) follow.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Class of evidence (Low Quality, Moderate Quality, High Quality, Meta-analysis, Systematic Review, Decision Analysis, Cost-Effectiveness Analysis, Guideline, and Reference) ratings are defined at the end of the &quot;Major Recommendations&quot; field.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Clinical Highlights&lt;/span&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Assess patients for symptoms and risk factors for COPD including asking about tobacco use/exposure at every visit. (&lt;em&gt;Annotations #1, 2; Aim #2&lt;/em&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tobacco cessation is the only known intervention that can slow progression of lung function loss. (&lt;em&gt;Annotations # 2; Aim #2&lt;/em&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Establish diagnosis and severity of COPD through spirometry, pre-and post-bronchodilator, in addition to history and physical examination. (&lt;em&gt;Annotation #1; Aim #1&lt;/em&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;After establishing severity, assess patient needs for pharmacologic and non-pharmacologic treatment and provide appropriate therapy as indicated. (&lt;em&gt;Annotations #4, 5, 6; Aims #3, 4&lt;/em&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Pulmonary rehabilitation is beneficial for patients with moderate to severe COPD (&lt;em&gt;Annotation #5; Aim #5&lt;/em&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;For patients with severe symptoms, despite maximal medical therapy, lung volume reduction surgery and transplantation may be an option. (&lt;em&gt;Annotations #5, 6&lt;/em&gt;) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Clinicians should discuss advance directives/health care directives and goals of care as early as possible. (&lt;em&gt;Annotation #6; Aim #5&lt;/em&gt;) &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;&lt;strong&gt;Chronic Obstructive Pulmonary Disease Algorithm Annotations&lt;/strong&gt;&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;1&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Establish Diagnosis of COPD&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;The Global Initiative for Chronic Obstructive Lung Disease (GOLD) defines COPD as follows:&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;A preventable and treatable disease characterized by chronic airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gas. Exacerbations and comorbidities contribute to the overall severity in individual patients. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Chronic obstructive bronchitis is defined as partially reversible airflow limitation as well as the presence of chronic productive cough for 3 months in each of 2 successive years in a patient in whom other causes of chronic cough have been excluded. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Emphysema is defined as an abnormal permanent enlargement of the air spaces distal to the terminal bronchioles, accompanied by destruction of their walls and without obvious fibrosis. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;[Guideline]&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Symptoms of and Risk Factors for COPD&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;COPD may be indicated by the presence of one of the following symptoms:&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Chronic cough (duration greater than 3 months) with or without sputum production &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Dyspnea with or without wheezing (exertional or at rest) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Wheezing, prolonged expiratory phase of respiration, rhonchi and cough &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Chronic sputum production &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Hyperinflation of the chest with increased anterior-posterior (A-P) diameter &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Use of accessory muscles of respiration &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pursed-lip breathing &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Signs of cor pulmonale:&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Increased pulmonic component of the second heart sound &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Neck vein distention &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Lower extremity edema &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Hepatomegaly&#xD;&#xA;            &lt;p&gt;NOTE: Finger clubbing is not characteristic of COPD and should alert the clinician to another condition such as idiopathic pulmonary fibrosis (IPF), cystic fibrosis, lung cancer or asbestosis.&lt;/p&gt;&#xD;&#xA;            &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;p&gt;COPD should also be considered if the patient has one or more of the following risk factors:&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;History of tobacco use or prolonged exposure to secondhand or environmental smoke &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Asthma &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Occupations with exposure to dust and chemicals (e.g., firefighters, welders) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Alpha 1-antitrypsin deficiency &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Chronic respiratory infections &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;p&gt;The diagnosis of COPD should be suspected based on the patient's medical history and physical examination, but spirometry is required to make a diagnosis and confirm the presence of persistent airflow limitation &lt;em&gt;[Guideline]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Spirometry&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Spirometry is an established and important method of measuring lung function for the diagnosis and management of patients with COPD. It is recommended for symptomatic patients at risk of COPD, particularly smokers greater than 45 years of age, and for regular follow-up of patients with documented COPD &lt;em&gt;[Systematic Review]&lt;/em&gt;. According to the GOLD criteria, COPD is defined as a forced expiratory volume in one second/forced vital capacity (FEV&lt;sub&gt;1&lt;/sub&gt;/FVC) ratio less than 70% after treatment &lt;em&gt;[Guideline]&lt;/em&gt;. Large population screening is not recommended.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Airflow obstruction is measured by spirometry and shows a reduced FEV&lt;sub&gt;1&lt;/sub&gt;/FVC ratio. Measuring pre-and post-bronchodilator spirometry is important to identify those patients with partial reversibility of airflow obstruction. Reversibility is defined as improvement in airflow by 12% of baseline and 200 mL of either FEV&lt;sub&gt;1&lt;/sub&gt; or FVC after administration of a bronchodilator. This does not exclude the diagnosis of COPD unless the ratio of FEV&lt;sub&gt;1&lt;/sub&gt;/FVC improves to greater than 70%.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;The signs, symptoms and airflow limitation in COPD vary with the severity of the disease. The stages of severity of COPD may be categorized according to the following table:&lt;/p&gt;&#xD;&#xA;    &lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: The stages of severity of COPD&quot;&gt;&#xD;&#xA;        &lt;thead&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Stage of COPD&lt;/th&gt;&#xD;&#xA;                &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;FEV&lt;sub&gt;1&lt;/sub&gt;/FVC &amp;lt;0.70 and FEV&lt;sub&gt;1&lt;/sub&gt;% Predicted&lt;/th&gt;&#xD;&#xA;                &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Typical Symptoms and Signs&lt;/th&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/thead&gt;&#xD;&#xA;        &lt;tbody&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Mild&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;80 or greater&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;No abnormal signs&lt;br /&gt;&#xD;&#xA;                &lt;br /&gt;&#xD;&#xA;                Cough (&amp;plusmn; sputum)&lt;br /&gt;&#xD;&#xA;                &lt;br /&gt;&#xD;&#xA;                Little or no dyspnea &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Moderate&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Between 50 and 79&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Breathlessness (&amp;plusmn; wheeze on moderate exertion)&lt;br /&gt;&#xD;&#xA;                &lt;br /&gt;&#xD;&#xA;                Cough (&amp;plusmn; sputum)&lt;br /&gt;&#xD;&#xA;                &lt;br /&gt;&#xD;&#xA;                Variable abnormal signs (general reduction in breath sounds, presence of wheezes)&lt;br /&gt;&#xD;&#xA;                &lt;br /&gt;&#xD;&#xA;                Hypoxemia may be present &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Severe&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Between 30 and 49&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot; rowspan=&quot;2&quot;&gt;Dyspnea with any exertion or at rest &lt;br /&gt;&#xD;&#xA;                &lt;br /&gt;&#xD;&#xA;                Wheeze and cough often prominent &lt;br /&gt;&#xD;&#xA;                &lt;br /&gt;&#xD;&#xA;                Lung hyperinflation usual; cyanosis, peripheral edema and polycythemia in advanced disease &lt;br /&gt;&#xD;&#xA;                &lt;br /&gt;&#xD;&#xA;                Hypoxemia and hypercapnia are common &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Very Severe&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Less than 30&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/tbody&gt;&#xD;&#xA;    &lt;/table&gt;&#xD;&#xA;    &lt;p&gt;The best correlation with morbidity and mortality is a decrease in FEV&lt;sub&gt;1&lt;/sub&gt;. With FEV&lt;sub&gt;1&lt;/sub&gt; greater than 1.0 L, there is a slight increase in mortality at 10 years. With FEV&lt;sub&gt;1&lt;/sub&gt; less than 0.75 L, the approximate mortality rate at one year is 30%, and at 10 years is 95%. Because of the relationship of prognosis and FEV&lt;sub&gt;1&lt;/sub&gt;, the severity of COPD is staged on the basis of this spirometry measurement. Patients are categorized as mild, moderate, severe or very severe. The COPD work group selected the COPD severity categories recommended by GOLD because they are straightforward and correlate with clinical experience. However, it is clear that there are widespread differences relative to disease severity classification among published guidelines &lt;em&gt;[Guideline]&lt;/em&gt;, &lt;em&gt;[Low Quality Evidence]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Pre- and Post-bronchodilator FEV&lt;sub&gt;1&lt;/sub&gt;&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;It is important to distinguish COPD from asthma, because treatment and prognosis differ. Measurement of pre- and post-bronchodilator FEV&lt;sub&gt;1&lt;/sub&gt; can assist with this differentiation. In asthma, the spirometric abnormality tends to return to normal with bronchodilators, although this distinction between COPD and asthma is not strictly rigid. If the FEV&lt;sub&gt;1&lt;/sub&gt;/FVC ratio improves to &amp;gt;70% after bronchial dilation, a diagnosis of COPD can be ruled out. Factors commonly used to distinguish COPD from asthma include age of onset, smoking history, triggering factors, and occupational history.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;If the results of available spirometry are unclear, formal spirometry in a pulmonary function test lab should be considered. Full pulmonary function tests with lung volumes and diffusion capacity (DLCO) can be helpful but are not necessary to establish diagnosis or severity of COPD.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Spirometry, interpretation strategies, selection of reference values, and quality control should be performed in compliance with the American Thoracic Society (ATS) Statement on Standardization of Spirometry &lt;em&gt;[Guideline]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Refer to the original guideline document for additional details.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Although peak flow meters should not be used to diagnose or monitor COPD, monitoring of peak expiratory flow at home and at work can be used in certain situations to determine reversibility and variability in airway obstruction.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Reversibility Testing (measurement of pre- and post-bronchodilator)&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Generally performed only once at time of diagnosis, this test is useful to help rule out asthma, to establish a patient's best attainable lung function, to gauge a patient's prognosis, and to guide treatment decisions.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Even patients who do not show a significant FEV&lt;sub&gt;1&lt;/sub&gt; response to a short-acting bronchodilator test can benefit symptomatically from long-term bronchodilator treatment.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;More than 20% variability in absolute measurement of serial peak expiratory flow may suggest asthma.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Atopy and marked improvement of spirometry with administration of bronchodilators or glucocorticosteroids favor the diagnosis of asthma.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Testing of bronchoconstrictor response is of doubtful clinical value in patients with established airflow limitation.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Significant reversibility as indicated by an increase of over 12% and 200 mL after inhaling a short-acting bronchodilator, may suggest asthma.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Alpha 1-Antitrypsin&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Alpha 1-antitrypsin deficiency (A1AD or Alpha-1) is a genetic disorder caused by defective production of alpha 1-antitrypsin (A1AT), leading to decreased A1AT activity in the blood and lungs, and deposition of excessive abnormal A1AT protein in liver cells &lt;em&gt;[Low Quality Evidence]&lt;/em&gt;. There are several forms and degrees of deficiency. Severe A1AD causes emphysema and/or COPD in adult life in nearly all people with the condition. Cigarette smoke is especially harmful to individuals with A1AD. In addition to increasing the inflammatory reaction in the airways, cigarette smoke directly inactivates alpha 1-antitrypsin by oxidizing essential methionine residues to sulfoxide forms, decreasing the enzyme activity by a factor of 2000. A1AD screening is appropriate in patients of Caucasian descent who develop COPD at a young age (less than 45 years) or who have a strong family history of the disease &lt;em&gt;[Guideline]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Differential Diagnosis&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Depending on the clinical scenarios, various disorders may be considered in the differential diagnosis of COPD, including:&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Asthma &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Alpha 1 anti-trypsin deficiency &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Bronchiectasis &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Heart failure &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Cystic fibrosis &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Cystic lung disease (lymphangioleiomyomatosis, pulmonary Langerhan's histiocytosis) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pulmonary fibrosis &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Upper airway lesions &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;p&gt;While a chest x-ray is not useful in the diagnosis of COPD, it can be useful to evaluate comorbidities or alternate diagnoses &lt;em&gt;[Guideline]&lt;/em&gt;. Chest computed tomography (CT) is not generally needed in the evaluation of COPD, but it can be useful if the diagnosis is not clear or if alternate diagnoses are considered.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;2&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Ask/Advise about Tobacco Use/Exposure at Every Visit and Offer Cessation Support as Needed&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Recommendation&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Patients with COPD should be given tools for tobacco cessation to prolong survival. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;p&gt;Ten percent to 15% of long-term smokers develop COPD with accelerated rates of decline in FEV&lt;sub&gt;1&lt;/sub&gt;. Advice and support from clinicians and other health professionals are potentially powerful influences on tobacco cessation. According to the U.S. Surgeon General, tobacco use is one of the most important public health issues of our time. The National Cancer Institute, which is the primary federal agency for tobacco control, states that the keys to patient awareness and education about tobacco cessation in a clinical setting are:&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;ASK about tobacco use at every visit&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;ADVISE all users to stop&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;ASSESS users' willingness to make a quit attempt&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;ASSIST users' efforts to quit&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;ARRANGE follow-up&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Reinforcement of tobacco cessation and follow-up for patients with COPD are extremely important. Pharmacotherapy, social support, and skills training/problem solving are the key treatments for tobacco cessation. Nicotine patches, nasal sprays, inhalers and oral medication are all available to help patients achieve cessation &lt;em&gt;[Guideline]&lt;/em&gt;, &lt;em&gt;[High Quality Evidence]&lt;/em&gt;. See the Implementation Tools and Resources Table in the original guideline for more information.&lt;/p&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;4&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Pharmacologic Management&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Each level of severity in the table below represents an intervention that should be considered only if the previous course of action fails to improve symptoms of COPD.&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;A table of estimated comparative daily dosages for inhaled corticosteroids appears in Appendix A, &quot;Estimated Comparative Daily Dosage for Inhaled Corticosteroids,&quot; in the original guideline document.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;A table of hydrofluoro-alkanes (HFAs) appears in Appendix B, &quot;Hydrofluoro-alkane (HFA) Directory,&quot; in the original guideline document.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Table&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;1&quot; summary=&quot;Table: Lung Function Parameters&quot;&gt;&#xD;&#xA;        &lt;tbody&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;                &lt;th class=&quot;Center&quot; valign=&quot;top&quot; colspan=&quot;2&quot;&gt;Lung Function Parameters&lt;/th&gt;&#xD;&#xA;                &lt;th class=&quot;Center&quot; valign=&quot;top&quot;&gt;Therapy&lt;/th&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot; colspan=&quot;3&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&lt;strong&gt;All severities&lt;/strong&gt;&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Smoking cessation support &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Oxygen supplementation &amp;ndash; when indicated &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Trigger avoidance &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Inhaler technique training &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;COPD education &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Caretaker support &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Assess current vaccine schedule &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;strong&gt;COPD Severity&lt;/strong&gt;&lt;/td&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;strong&gt;FEV&lt;sub&gt;1&lt;/sub&gt; % Predicted&lt;/strong&gt;&lt;/td&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&lt;strong&gt;FEV&lt;sub&gt;1&lt;/sub&gt;/FVC&lt;/strong&gt;&lt;/td&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot;&gt;&lt;strong&gt;Add:&lt;/strong&gt;&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Mild&lt;/td&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&amp;ge;80%&lt;/td&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&amp;lt;0.7&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Short-acting bronchodilators as needed for symptoms &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Moderate&lt;/td&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;50%-79%&lt;/td&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&amp;lt;0.7&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Daily long-acting bronchodilators &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Pulmonary rehabilitation &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Inhaled corticosteroids are indicated if hospitalized for frequent COPD exacerbations &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Consider adding a PDE4 inhibitor &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Severe&lt;/td&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;30%-49%&lt;/td&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&amp;lt;0.7&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Daily long-acting bronchodilators as above plus inhaled corticosteroids to reduce exacerbations &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Oral steroid bursts for exacerbations &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Very severe&lt;/td&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&amp;lt;30% or&lt;br /&gt;&#xD;&#xA;                &amp;lt;50% plus&lt;br /&gt;&#xD;&#xA;                chronic respiratory failure &lt;/td&gt;&#xD;&#xA;                &lt;td class=&quot;Center&quot; valign=&quot;top&quot;&gt;&amp;lt;0.7&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&#xD;&#xA;                &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;                    &lt;li&gt;Combination therapy as above &lt;/li&gt;&#xD;&#xA;                    &lt;li&gt;Oral steroids as needed &lt;/li&gt;&#xD;&#xA;                &lt;/ul&gt;&#xD;&#xA;                &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/tbody&gt;&#xD;&#xA;    &lt;/table&gt;&#xD;&#xA;    &lt;p class=&quot;Note&quot;&gt;COPD, chronic obstructive pulmonary disease; PDE4, phosphodiesterase 4&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Bronchodilator Medications&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Summary&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Albuterol is the preferred agent for as-needed control of symptoms in patients with mild COPD and as an additive as-needed agent to a scheduled bronchodilator in patients with more severe COPD because the onset of bronchodilator effect (15 minutes) is more rapid than ipratropium (30&amp;ndash;90 minutes).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Tiotropium has been shown to be a superior scheduled bronchodilator to salmeterol and ipratropium.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;As a scheduled bronchodilator, salmeterol has the main advantage of requiring only twice-daily dosing, and therefore may improve compliance.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Albuterol and ipratropium are equipotent as bronchodilators, improving dyspnea and exercise tolerance equally well. Salmeterol is a long-acting bronchodilator that is a suitable agent for scheduled administration &lt;em&gt;[High Quality Evidence]&lt;/em&gt;, &lt;em&gt;[Low Quality Evidence]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Refer to the original guideline document for additional information on bronchodilator medications.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Glucocorticosteroids&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;The effects of both inhaled and oral corticosteroids are much less robust in patients with COPD when compared to asthma. Therefore, the role of glucocorticosteroids in the management of stable COPD is limited to specific situations &lt;em&gt;[Guideline]&lt;/em&gt;. The dose-response relationships and long-term safety of inhaled glucocorticosteroids are not known.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Inhaled Glucocorticosteroids&lt;/strong&gt;: Regular use of inhaled corticosteroids does not modify the decline in FEV&lt;sub&gt;1&lt;/sub&gt; observed in patients with COPD &lt;em&gt;[High Quality Evidence]&lt;/em&gt;. However, with regular treatment, inhaled steroids have been shown to reduce the frequency of exacerbations and improve health status in patients with FEV&lt;sub&gt;1&lt;/sub&gt; less than 50% predicted and history of frequent exacerbations. An inhaled corticosteroid combined with a long-acting beta-2-agonist is more effective than the individual components in reducing exacerbations and improving lung function as well as health status. However, treatment with inhaled glucocorticosteroids or a combination inhaler increases the likelihood of pneumonia and does not reduce overall mortality &lt;em&gt;[High Quality Evidence]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Oral Glucocorticosteroids&lt;/strong&gt;: There is insufficient evidence to recommend a therapeutic trial of oral glucocorticosteroids in patients with COPD to determine whether a patient will benefit from long-term treatment of either oral or inhaled glucocorticosteroids. There is also insufficient evidence to demonstrate that long-term use of an oral glucocorticosteroid provides benefits for patients with COPD. Given the toxicity of long-term treatment and the lack of prospective studies on the long-term effects, long-term treatment with oral glucocorticosteroids is not recommended in the management of stable COPD &lt;em&gt;[Guideline]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Oral corticosteroids in modest doses (30 to 40 mg a day of prednisone or its equivalent) and for no longer than 2 weeks are indicated in the treatment of acute exacerbations of COPD &lt;em&gt;[High Quality Evidence]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Phosphodiesterase 4 Inhibitors&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Roflumilast&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Roflumilast is an oral phosphodiesterase inhibitor approved for use in COPD in a dose of 500 mcg daily. Studies have shown a statistically significant though modest improvement in airflow and a reduction in exacerbations. A history of frequent exacerbation, chronic bronchitis, cough and sputum production have predicted a higher chance of benefit. It appears to add benefit in patients receiving inhaled corticosteroids or long-acting beta-agonists, but use of roflumilast has not been evaluated in those receiving long-acting muscarinic antagonists. Noted side effects have included weight loss, nausea, diarrhea and headache. It is metabolized by the liver, and its use is contraindicated in those with moderate to severe hepatic impairment. The exact place in treatment is not defined, but it is a reasonable alternative for patients with moderate to very severe COPD with recurrent exacerbations &lt;em&gt;[Systematic Review]&lt;/em&gt;, &lt;em&gt;[High Quality Evidence]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Methods of Drug Delivery&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Metered Dose Inhaler (MDI) with Spacer&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Some studies support the use of spacers to obtain effective MDI drug delivery. The increased distance slows the velocity of the fine particles, increasing their chances of reaching the bronchial tree. It is of utmost importance to train and retrain patients, nurses, clinicians, and pharmacists in proper inhaler technique for optimal drug delivery. Evidence of the effectiveness of one type of spacer over another is variable and controversial.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Chlorofluorocarbons (CFCs) are freon compounds commonly used as propellants in commercial aerosols including MDIs. Concerns have been raised about the toxicity of freon and its role in depleting the ozone layer. The production of ozone-depleting substances is being phased out worldwide under terms of an international agreement. According to the Federal Drug Administration, a few CFC-containing inhalers remain on the market, but are in the process of being phased out:&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Combination albuterol and ipratropium inhalation aerosol &amp;ndash; will be transitioned to Respimat&amp;trade; device in early 2013 &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pirbuterol autohaler &amp;ndash; last date for sale: December 31, 2013 &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;p&gt;Hydrofluoro-alkane (HFA) is now used as the propellant in many MDIs. Clinicians should be aware of some important points regarding these inhalers and instruct patients accordingly:&lt;/p&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Particle size is smaller with HFA propellants than CFC. This produces a mist that may feel different to the patient. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Priming the inhaler requires two to four pumps. The inhaler should be re-primed if not used for 2 weeks. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Manufacturers recommend cleaning the casing every 2 weeks to prevent clogging of the nozzle. &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;p&gt;The &lt;a href=&quot;http://www.uptodate.com/contents/asthma-inhaler-techniques-in-adults-beyond-the-basics&quot; title=&quot;UpToDate Web site&quot;&gt;UpToDate Web site&lt;/a&gt; reviews patient information for metered-dose types of inhalers, inhaler technique and basic cleaning instructions for inhalers (for subscribers).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Dry Powder Inhaler (DPI)&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;DPIs are an alternative to metered-dose inhalers and are strongly supported by study data. DPIs deliver drugs in dry powder form without the use of propellants. In addition, DPIs are breath-activated, eliminating the need to synchronize inhalation with actuation.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;DPIs have been developed as a response to concerns about freon toxicity. Newer DPIs products deliver pure drug from self-enclosed, multiple-dose devices that help avoid the potential adverse effects of additives used in MDIs.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;The &lt;a href=&quot;http://www.uptodate.com/contents/asthma-inhaler-techniques-in-adults-beyond-the-basics#H11&quot;&gt;UpToDate Web site&lt;/a&gt; reviews patient information for dry powder types of inhalers, inhaler technique and basic cleaning instructions for inhalers (for subscribers).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Refer to Appendix B in the original guideline document for a hydrofluoro-alkane directory.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Nebulizers&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Aerosol therapy via nebulizer is generally considered expensive, inconvenient and inefficient. Nebulizer therapy should be considered a second choice when compared with other modes of aerosol delivery (e.g., MDIs and DPIs). Patients incapable of performing MDI or DPI maneuver may benefit from nebulizer therapies.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Theophylline&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Theophylline has a narrow therapeutic index with potentially significant adverse effects and drug interactions that must be carefully considered and closely monitored during therapy.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Refer to the original guideline document for additional information on theophylline.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Other Pharmacologic Interventions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Antibiotics&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;The routine use of antibiotics is not recommended except for treatment of bacterial exacerbations of COPD.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;See Annotation #9, &quot;Treatment,&quot; for more information.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Azithromycin&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Azithromycin taken daily for 1 year, when added to usual treatment, decreased the frequency of exacerbations and improved quality of life &lt;em&gt;[High Quality Evidence]&lt;/em&gt;. Due to the long-term side effects and potential colonization with macrolide resistant bacteria, this should not be initiated without a specialty consultation.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Antitussives&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Regular use of antitussives is not recommended in COPD since cough can have a significant protective effect.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Antiviral Agents&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Antiviral medications are available to treat and prevent influenza, but should not be used as a substitute for vaccination unless it is contraindicated. When treatment with antivirals is initiated within 48 hours of symptom onset, severity and duration of symptoms may be reduced.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;There are two types of antiviral medications for influenza: adamantanes and neuraminidase inhibitors. The choice of antiviral therapy should follow guidance from public health authorities based on the strain of influenza currently circulating (see this Web address for more information: &lt;a href=&quot;http://www.cdc.gov/flu/professionals/antivirals/index.htm&quot; title=&quot;CDC Flu Web site&quot; target=&quot;_blank&quot;&gt;http://www.cdc.gov/flu/professionals/antivirals/index.htm&lt;/a&gt;).&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Leukotriene Modifiers&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;This drug class has not been adequately tested in COPD patients, and its use cannot be recommended until additional evidence relative to its efficacy is available.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Mucolytics&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;In theory, reducing mucus viscosity and enhancing cough clearance or mucociliary clearance of mucus could improve pulmonary function and reduce the incidence of respiratory infections in individuals with COPD. Ideally, treatment would result in both objective (increase in FEV&lt;sub&gt;1&lt;/sub&gt;) and subjective (better sense of well-being) improvement for those individuals.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;To date, there has been no conclusive evidence for significant improvement in pulmonary function with any of the agents studied so far. Guaifenesin is widely used as an over-the-counter expectorant, but documented objective or even subjective improvement has not been consistently demonstrated. &lt;em&gt;[Low Quality Evidence]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Oral Beta Agonists&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Inhaled bronchodilator therapy is preferred.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Vaccines&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Influenza and pneumococcal pneumonia together are the sixth leading cause of death in the U.S. among persons 65 years of age and older. Immunization with pneumococcal and influenza vaccines is recommended by the U.S. Public Health Service's Advisory Committee on Immunization Practices to reduce infectious complications involving the respiratory tract. All patients should be current with recommended vaccinations; however, clinicians need to ensure patients with COPD receive the following vaccinations related to respiratory conditions:&lt;/p&gt;&#xD;&#xA;    &lt;blockquote&gt;&#xD;&#xA;    &lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Pneumococcal&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;The pneumococcal vaccine (pneumococcal conjugate vaccine [PCV13] and pneumococcal polysaccharide vaccine [PPSV23]) is recommended for adults older than 65 or with certain risk factors. Recommendations can be found at the &lt;a href=&quot;http://www.cdc.gov/vaccines/vpd-vac/pneumo/default.htm&quot; title=&quot;CDC Vaccine Web site&quot; target=&quot;_blank&quot;&gt;CDC Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Influenza&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Influenza vaccine should be provided on an annual basis because of new antigens and waning immunity from the previous year. The optimal time for influenza vaccination is usually from early October through mid-November. To avoid a missed opportunity, vaccination can be done as soon as vaccine is available, but not prior to September. Vaccine may be given even after flu activity is known to be occurring in the community &lt;em&gt;[Low Quality Evidence]&lt;/em&gt;, &lt;em&gt;[Guideline]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Tdap - combined tetanus diphtheria and pertussis vaccines)&lt;/span&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Recommendations for Tdap can be found at the &lt;a href=&quot;http://www.cdc.gov/vaccines/vpd-vac/combo-vaccines/DTaP-Td-DT/Tdap.htm&quot; title=&quot;CDC Web site&quot; target=&quot;_blank&quot;&gt;CDC Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;/blockquote&gt;&lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;5&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Non-Pharmacologic Interventions&lt;/strong&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Recommendations&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Pulmonary rehabilitation programs are effective in improving exercise capacity, quality of life, and perception of symptoms, regardless of age &lt;em&gt;[Low Quality Evidence]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Long-term oxygen therapy (more than 15 hours per day) improves survival and quality of life in hypoxemic patients. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Pulmonary Rehabilitation Program&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;The primary goal of pulmonary rehabilitation is to decrease symptoms, improve quality of life, and increase participation in everyday activities. To achieve these goals, pulmonary rehabilitation uses a multidisciplinary approach, including education and exercise training, and should be considered for patients with moderate, severe and very severe COPD &lt;em&gt;[Guideline]&lt;/em&gt;. Benefits have been demonstrated from rehabilitation programs conducted in inpatient, outpatient and home settings &lt;em&gt;[Guideline]&lt;/em&gt;, &lt;em&gt;[Meta-analysis]&lt;/em&gt;, &lt;em&gt;[High Quality Evidence]&lt;/em&gt;. Pulmonary rehabilitation has been evaluated in several large clinical trials. The various benefits are listed below.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Benefits of Pulmonary Rehabilitation in COPD&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Improves exercise capacity &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Reduces perceived intensity of breathlessness &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Improves health-related quality of life &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Reduces the number of hospitalizations and days in hospital &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Reduces anxiety and depression associated with COPD &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Strength and endurance training of the upper limbs improves arm function &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Benefits extend well beyond the immediate period of training &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Respiratory muscle training is beneficial, especially when combined with general exercise training &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Psychosocial intervention is helpful &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;p&gt;Patients with moderate, severe or very severe COPD have shown benefit from exercise training programs with an improvement in exercise tolerance and a reduction in dyspnea and fatigue. These benefits do appear to wane after the program ends, but if exercise is maintained at home, the patient's health status continues to remain above pre-rehab levels &lt;em&gt;[High Quality Evidence]&lt;/em&gt;. There currently is not sufficient evidence to determine whether repeated courses increase the likelihood a patient will maintain the benefits gained during the initial course.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Refer to Appendix D, &quot;Summary of Structure and Services &amp;ndash; Pulmonary Rehabilitation Program,&quot; in the original guideline document.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Oxygen Therapy&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Important Points&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Long-term oxygen therapy (more than 15 hours per day) improves survival and quality of life in patients with resting hypoxemia. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pulse oximetry is a good method for monitoring oxygen saturation and can be used in adjusting the oxygen flow setting. If the results are indefinite, then an arterial blood gas measurement should be obtained. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Indications for long-term oxygen therapy have been adopted by Medicare as reimbursement criteria.* &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Patients considered for long-term therapy may benefit from assessment by a pulmonologist. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Supplemental long-term oxygen therapy should be provided at a flow rate sufficient to produce a resting partial pressure of oxygen in arterial blood (P&lt;sub&gt;a&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt;) of greater than 55 mm Hg, or arterial oxygen concentration (S&lt;sub&gt;a&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt;) greater than 89%. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Titrate liter flow to goal at rest: add 1 L/min during exercise or sleep or titrate during exercise to goal of S&lt;sub&gt;a&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt; greater than 89%. Titrate sleep liter flow to 8-hour sleep of S&lt;sub&gt;a&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt; greater than 89%. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Consider referral for sleep evaluation if patient experiences cyclic desaturation during sleep but is normoxemic at rest. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Recheck S&lt;sub&gt;a&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt; or P&lt;sub&gt;a&lt;/sub&gt;O&lt;sub&gt;2&lt;/sub&gt; in 1 to 3 months if hypoxia developed during an acute exacerbation. Rechecks should be performed annually if hypoxia is discovered in an outpatient with stable COPD. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;The benefits of long-term oxygen therapy for patients without resting hypoxemia but with exercise or sleep-related hypoxemia have not been determined and are being addressed by the LOTT Trial, sponsored by the National Heart, Lung, and Blood Institute (NHLBI) &lt;em&gt;[Low Quality Evidence]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;p class=&quot;Note&quot;&gt;*Refer to Appendix C in the original guideline document for a summary of Medicare Oxygen Coverage guidelines.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Oxygen Delivery Methods&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;The dual-prong nasal cannula is the standard means of continuous flow oxygen delivery for the stable COPD patient with hypoxemia. It is not only well-tolerated, but is also simple and reliable. Care must be taken when assigning an estimated forced inspiratory oxygen (FiO&lt;sub&gt;2&lt;/sub&gt;) to patients as this low-flow system can have great fluctuations &lt;em&gt;[Guideline]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Reservoir cannulas, demand pulse delivery devices, and transtracheal oxygen delivery are oxygen-conserving devices that can improve the portability of oxygen therapy, reduce the overall costs of home oxygen therapy, especially in patients requiring higher flow rates, and can more effectively treat refractory hypoxemia. These devices function by delivering all of the oxygen during early inhalation. They reduce oxygen requirements by 25% to 75% compared to continuous flow oxygen. Disadvantages of these devices are that they are bulky on the face, mechanically more complicated, and require additional care as well as additional training of the user &lt;em&gt;[Low Quality Evidence]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;COPD and Air Travel&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Airline travel is safe for most patients with COPD. Hypoxemic patients should be evaluated clinically, and a decision should be made regarding oxygen requirements. Patients with COPD receiving continuous oxygen at home will require supplementation during flight.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Many airlines will allow the use of battery-operated portable oxygen concentrators (POCs) on board during flight. POCs were first approved for use by the FAA in the summer of 2005.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Each airline has its own policy regarding on-board oxygen transport and in-flight oxygen usage. Patients need to contact the airline for their current policies regarding oxygen.&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Patients should notify oxygen supply company 2 weeks in advance. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Many airlines have their own airline specific medical form for the physician to fill out. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;POC rentals can be per day/week/month. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Patients should always carry a copy of their oxygen prescription. &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Surgical Options for Severe Disease&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Lung Volume Reduction Surgery (LVRS) for Emphysema&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;The goal of LVRS is to relieve disabling dyspnea in patients in whom emphysema has limited activities of daily living and has proved refractory to optimal medical management. Following surgery, improvement has been noted in lung elastic recoil, respiratory function, ventilation/perfusion matching, and cardiovascular function. A variety of surgical approaches and reduction techniques have been used. Results of the National Emphysema Treatment Trial (NETT) have been published.&lt;/p&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Overall, LVRS did not demonstrate a survival advantage over medical therapy. Lung volume reduction surgery only yielded a survival advantage for patients with upper lobe emphysema and low baseline exercise capacity. LVRS demonstrated increased mortality and no functional improvement for patients with non-upper lobe emphysema. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;LVRS showed improvement in exercise capacity only among a small subgroup of patients: those with upper lobe emphysema. Most patients' improvements returned to baseline after two years. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Significantly more patients with upper lobe emphysema randomized to LVRS had improved quality of life after 2 years as compared to non-surgical patients. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Due to the strictness of the exclusion criteria, conclusions from the NETT trial cannot be extended to the general population of patients with emphysema. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Pre-operative evaluation includes ability to complete a 6-minute walk of over 140 meters, completion of a pulmonary rehabilitation program, full pulmonary function tests, chest CT, echocardiogram, and possibly a right heart catheterization and a radionuclide stress test. &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;LVRS should only be performed in medical centers with appropriately trained surgeons and availability of necessary equipment. &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;[Guideline]&lt;/em&gt;, &lt;em&gt;[High Quality Evidence]&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Bronchoscopic Lung Volume Reduction (LVR)&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Bronchoscopic LVR is being assessed in clinical trials; its role in management of COPD is yet to be defined.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Bullectomy&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Giant bullous emphysema is a rare subset of patients in whom single or multiple large bullae encompass 30% or more of a hemithorax, often displacing potentially functional lung tissue as these large airspaces increase in volume. In appropriate cases, surgical resection of these bullae can restore significant pulmonary function and improve symptoms. CT scan is essential in evaluating these patients and referral to a pulmonary specialist is indicated &lt;em&gt;[High Quality Evidence]&lt;/em&gt;, &lt;em&gt;[Low Quality Evidence]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;Lung Transplantation&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Unilateral or bilateral lung transplantation is a treatment option in highly selected patients with severe COPD &lt;em&gt;[High Quality Evidence]&lt;/em&gt;. A few studies show improvement in quality-of-life parameters but no increase of survivability &lt;em&gt;[Low Quality Evidence]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;General Selection Guidelines for Candidate Selection for Lung Transplantation in COPD Patients&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;table border=&quot;1&quot; cellspacing=&quot;1&quot; cellpadding=&quot;3&quot; summary=&quot;Table: General Selection Guidelines for Candidate Selection for Lung Transplantation in COPD Patients&quot;&gt;&#xD;&#xA;        &lt;tbody&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Relative Contraindications&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Age limits:&#xD;&#xA;                &lt;p&gt;Heart-lung transplants: ~55 yrs&lt;br /&gt;&#xD;&#xA;                Double lung transplant: ~60 yrs&lt;br /&gt;&#xD;&#xA;                Single lung transplant: ~65 yrs&lt;/p&gt;&#xD;&#xA;                Symptomatic osteoporosis&lt;br /&gt;&#xD;&#xA;                Oral corticosteroids greater than 20 mg/day &lt;br /&gt;&#xD;&#xA;                Psychosocial problems&lt;br /&gt;&#xD;&#xA;                Requirement for invasive mechanical ventilation&lt;br /&gt;&#xD;&#xA;                Human immunodeficiency virus (HIV) infection &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Absolute Contraindications&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Severe musculoskeletal disease affecting the thorax&lt;br /&gt;&#xD;&#xA;                Substance addiction within previous 6 months&lt;br /&gt;&#xD;&#xA;                Dysfunction of extrathoracic organ, particularly renal dysfunction&lt;br /&gt;&#xD;&#xA;                Active malignancy within 2 years except basal or squamous cell carcinoma of skin&lt;br /&gt;&#xD;&#xA;                Hepatitis B antigen positive&lt;br /&gt;&#xD;&#xA;                Hepatitis C with biopsy-proven evidence of liver disease &lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/tbody&gt;&#xD;&#xA;    &lt;/table&gt;&#xD;&#xA;    &lt;p&gt;&lt;em&gt;[Low Quality Evidence]&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Following the position of the American Thoracic Society and the European Respiratory Society &lt;em&gt;[Guideline]&lt;/em&gt;, appropriate candidate selection is as follows:&lt;/p&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;FEV&lt;sub&gt;1&lt;/sub&gt; less than or equal to 25% predicted (without reversibility) &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Resting room air partial pressure of carbon dioxide in arterial blood (PaCO&lt;sub&gt;2&lt;/sub&gt;) greater than 55 mm Hg &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Elevated PaCO&lt;sub&gt;2&lt;/sub&gt; with progressive deterioration requiring long-term oxygen therapy &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Elevated pulmonary arterial pressure with progressive deterioration &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;&lt;/ol&gt;&#xD;&#xA;&lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;6&quot;&gt;&#xD;&#xA;    &lt;li&gt;&lt;strong&gt;Ongoing Management&lt;/strong&gt;&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&lt;/ul&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Schedule Regular Follow-Up Visits&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;Follow-up visits should be jointly established between primary care clinicians and pulmonary specialists, and should be tailored to the learning stage and comorbidities of individual patients. Spirometry should be included as part of the follow-up care &lt;em&gt;[Guideline]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;The exact frequency of clinician visits is a matter of clinical judgment; however, the following may serve as a general guide for patients with stable COPD.&lt;/p&gt;&#xD;&#xA;        &lt;table border=&quot;0&quot; cellspacing=&quot;5&quot; cellpadding=&quot;10&quot; summary=&quot;Table: Schedule Regular Follow-Up Visits&quot;&gt;&#xD;&#xA;            &lt;thead&gt;&#xD;&#xA;                &lt;tr&gt;&#xD;&#xA;                    &lt;th valign=&quot;top&quot;&gt;Severity&lt;/th&gt;&#xD;&#xA;                    &lt;th valign=&quot;top&quot;&gt;Regular Follow-Up Visit&lt;/th&gt;&#xD;&#xA;                &lt;/tr&gt;&#xD;&#xA;            &lt;/thead&gt;&#xD;&#xA;            &lt;tbody&gt;&#xD;&#xA;                &lt;tr&gt;&#xD;&#xA;                    &lt;td valign=&quot;top&quot;&gt;Mild&lt;/td&gt;&#xD;&#xA;                    &lt;td valign=&quot;top&quot;&gt;Yearly&lt;/td&gt;&#xD;&#xA;                &lt;/tr&gt;&#xD;&#xA;                &lt;tr&gt;&#xD;&#xA;                    &lt;td valign=&quot;top&quot;&gt;Moderate&lt;/td&gt;&#xD;&#xA;                    &lt;td valign=&quot;top&quot;&gt;3 to 6 months&lt;/td&gt;&#xD;&#xA;                &lt;/tr&gt;&#xD;&#xA;                &lt;tr&gt;&#xD;&#xA;                    &lt;td valign=&quot;top&quot;&gt;Severe&lt;/td&gt;&#xD;&#xA;                    &lt;td valign=&quot;top&quot;&gt;2 to 4 months or more frequently as needed&lt;/td&gt;&#xD;&#xA;                &lt;/tr&gt;&#xD;&#xA;            &lt;/tbody&gt;&#xD;&#xA;        &lt;/table&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Evaluation of COPD Symptoms and Monitoring of Comorbidities&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;In treating patients with COPD, it is important to consider the presence of concomitant conditions such as bronchial carcinoma, tuberculosis, sleep apnea, depression, pulmonary embolism, osteoporosis, and heart failure. The appropriate diagnostic tools (chest radiograph, electrocardiogram, etc.) and referral to clinical specialists should be used whenever symptoms (e.g., hemoptysis) suggest one of these conditions &lt;em&gt;[Guideline]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Refer to Consult with Pulmonary Specialist&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;Obtaining the opinion of a pulmonary specialist may be beneficial at any stage of the disease. Referral may be indicated to confirm the diagnosis, facilitate tobacco cessation, and optimize appropriate treatment.&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;Consider referral/consultation (if available):&lt;/p&gt;&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;When lung function deficits are not consistent with symptoms &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;To confirm the diagnosis and rule out other diagnoses &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;When pulmonary function tests show mixed restrictive and obstructive lung disease &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;When patient with COPD has less than 10-year pack history of smoking &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;When considering alpha-1 antitrypsin deficiency (age 45 or younger or strong family history) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;When patient has been hospitalized for COPD &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;When patient has frequent respiratory infections or exacerbations &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;When patient has a rapid decline in FEV&lt;sub&gt;1&lt;/sub&gt; &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;For consideration/monitoring of oxygen therapy &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;When patient may be a candidate for lung transplantation or volume reduction surgery &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;When uncomfortable with managing patient alone &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Discuss Advance Care Planning, Health Care Directives or Living Will&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;Many patients have an interest in discussing advance care plans, but their wishes tend to be passive and unspoken.&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;Clinicians are encouraged to initiate and facilitate conversations about advance care planning with all COPD patients at routine outpatient visits. See Appendix E, &quot;ICSI Shared Decision-Making Model,&quot; in the original guideline document.&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;It is also helpful to discuss specific treatment preferences throughout the course of the disease. In patients with severe disease, treatment preferences may include home care only, hospitalization for comfort care, initiation of full life support if there is a reasonable chance for recovery to functional independence, or continuation of indefinite life support in a chronic nursing facility.&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;&lt;em&gt;Objectives of Discussion&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;To encourage clinicians to discuss advance care planning with COPD patients &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;To give patients control over their health care decisions &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;To reassure that patients' wishes will be carried out at the end of their life &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;To increase the number of COPD patients who have written health care directives &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;To increase the number of patients with severe COPD who have discussed specific treatment preferences and goals of care &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;To name a durable power of attorney for health care or an appropriate proxy decision maker &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;p&gt;&lt;em&gt;Plan for Discussion&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;For the patient with moderate to severe COPD, at a routine office visit, ask the question, &lt;em&gt;&lt;strong&gt;&quot;Do you have a living will, advance care plan or advance directives?&quot;&lt;/strong&gt;&lt;/em&gt;&#xD;&#xA;            &lt;p&gt;Action: If &lt;strong&gt;&lt;em&gt;yes&lt;/em&gt;&lt;/strong&gt;, request that a copy be placed in the patient's medical record.&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Note: If this document was written before the patient's COPD symptoms became moderate to severe, the document may need updating.&lt;/p&gt;&#xD;&#xA;            &lt;p&gt;Action: If &lt;strong&gt;&lt;em&gt;no&lt;/em&gt;&lt;/strong&gt;, offer the patient written information on&amp;nbsp;advance care planning, including health care directives, encourage him/her to discuss this with family members or a close friend, and offer to discuss any questions at the next office visit.&lt;/p&gt;&#xD;&#xA;            &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;An advance care plan should include patient treatment preferences in regards to hospitalization, life support (including cardiopulmonary resuscitation, endotracheal intubation and non-invasive ventilation), and end-of-life care.&lt;br /&gt;&#xD;&#xA;            &lt;em&gt;&lt;strong&gt;&lt;/strong&gt;&lt;/em&gt;&#xD;&#xA;            &lt;p&gt;Action: Document the patient's treatment preferences in the patient's medical record and request that a copy of the advance care plan with the health care directive be placed in the patient's medical record.&lt;/p&gt;&#xD;&#xA;            &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;p&gt;See the NGC summary of the ICSI guideline &lt;a href=&quot;/content.aspx?id=47629&quot; title=&quot;Guideline #10131&quot;&gt;Palliative Care for Adults&lt;/a&gt; for more information regarding advance care planning.&lt;/p&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;7&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;strong&gt;Acute Exacerbation&lt;/strong&gt;&#xD;&#xA;        &lt;p&gt;Signs and symptoms of an acute exacerbation of COPD may include any of the following:&lt;/p&gt;&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Increased dyspnea &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Increased heart rate &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Increased cough &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Increased sputum production &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Change in sputum color or character &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Use of accessory muscles of respiration &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Peripheral edema &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Development or increase in wheezing &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Change in mental status &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Fatigue &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Fever &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Increased respiratory rate &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Decrease in FEV&lt;sub&gt;1&lt;/sub&gt; or peak expiratory flow &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Hypoxemia &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Chest tightness &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;p&gt;Change in mental status or a combination of two or more of the following new symptoms indicates a severe acute exacerbation:&lt;/p&gt;&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Dyspnea at rest &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Cyanosis &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Respiratory rate of greater than 25 breaths per minute &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Heart rate of greater than 110 beats per minute &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Use of accessory muscles of respiration &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;8&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;strong&gt;Evaluation&lt;/strong&gt;&#xD;&#xA;        &lt;p&gt;When a patient with known COPD presents with a moderate to severe exacerbation, the following key elements of the history, physical examination and laboratory/radiology evaluation should be considered:&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;History&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Baseline respiratory status &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Present treatment regimen and recent medication use &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Signs of airway infection (e.g., fever and/or change in volume and/or color of sputum) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Duration of worsening symptoms &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Limitation of activities &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;History of previous exacerbations &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Increased cough &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Decrease in exercise tolerance &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Chest tightness &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Change in alertness &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Other non-specific symptoms including malaise, difficulty sleeping and fatigue &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Symptoms associated with comorbid acute and chronic conditions &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Although rarely used, non-selective beta-blockers may contribute to bronchospasms &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Physical Examination&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Measurement of heart rate and blood pressure &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Measurement of respiratory rate &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Measurement of oxygen saturations using pulse oximetry &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Measurement of temperature &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Respiratory distress &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Accessory respiratory muscle use &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Increased pulmonary findings (e.g., wheezing, decreased air entry, prolonged expiratory phase) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Peripheral edema &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Somnolence and/or hyperactivity &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Acute comorbid conditions &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Laboratory/Radiology&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Chest radiograph to exclude alternative diagnosis &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Arterial blood gas (in patients with an oxygen saturation less than 88%, positive history of hypercapnia, questionable accuracy of oximetry, somnolence or other evidence of impending respiratory failure [e.g., respiratory rate greater than 40 breaths per minute]) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Theophylline level (if theophylline is being utilized) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;A sputum culture with susceptibilities, if available, should be performed when an infectious exacerbation does not respond to initial antibiotic treatment &lt;em&gt;[Guideline]&lt;/em&gt;. It is important that the sputum specimen is of good quality. &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Brain natriuretic peptide (BNP), a simple blood lab test, can be of some use in evaluating a patient presenting with dyspnea, although its interpretation needs to be carefully applied along with clinical and other lab data such as chest radiograph and echocardiogram. Its sensitivity and specificity in this setting increase at levels above 400 but do not differentiate between acute left ventricular (LV) failure, cor pulmonale or pulmonary embolism &lt;em&gt;[Low Quality Evidence]&lt;/em&gt;. It is of particular value if the level is very low. The probability of left ventricular failure as a cause of dyspnea is less than 10% if the BNP is less than 100 &lt;em&gt;[Low Quality Evidence]&lt;/em&gt;. &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;p&gt;In patients with an acute COPD exacerbation, spirometry is of little value. For that reason, oximetry and/or arterial blood gases should be monitored.&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;There is little evidence regarding the contribution of additional laboratory testing or the usefulness of electrocardiography or echocardiography in an acute exacerbation of COPD. They may be a useful consideration if the diagnosis is unclear, in order to evaluate other comorbid conditions &lt;em&gt;[Systematic Review]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;9&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;strong&gt;Treatment&lt;/strong&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Recommendations&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Albuterol or levalbuterol should be given in the setting of an acute exacerbation of COPD. &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Ipratropium may be added to produce additive bronchodilation and allow the use of lower doses of albuterol or levalbuterol. &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Steroids should be used in acute exacerbations. &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Clinicians must monitor oxygen saturation or arterial blood gas measurement. &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Consider the use of antibiotics in the presence of an exacerbation with purulent sputum. &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Bronchodilators&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;Albuterol and levalbuterol are the preferred bronchodilator in the setting of an acute exacerbation of COPD because of its rapid onset of action. If clinical improvement does not occur promptly, ipratropium may be added to produce additive bronchodilation and allow the use of lower doses of albuterol or levalbuterol, thus diminishing dose-dependent toxicity. Administration of either agent by MDI and spacer or by nebulization is acceptable &lt;em&gt;[Meta-analysis]&lt;/em&gt;, &lt;em&gt;[High Quality Evidence]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Systemic Steroids&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;Studies have demonstrated the benefits of systemic glucocorticosteroids in the management of COPD exacerbations. Doses of oral prednisone at 30 to 40 mg a day for 7 to 14 days have been shown to reduce symptoms and reduce the likelihood of hospitalization. Treatment beyond 2 weeks does not provide any additional benefit, but does increase the likelihood of significant side effects such as hyperglycemia. There is no need to discontinue inhaled steroids while the patient is taking oral prednisone &lt;em&gt;[High Quality Evidence]&lt;/em&gt;, &lt;em&gt;[Low Quality Evidence]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Antibiotics&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;Because one-third to one-half of all COPD exacerbations appears to be caused by bacterial infections, antibiotic use is frequently indicated. Viruses can also be detected in one-third to two-thirds of exacerbations when culture, serology and PCR-based testing are used. There is a relationship between exacerbation occurrence and new bacterial pathogen acquisition &lt;em&gt;[Low Quality Evidence]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;The GOLD 2011 guideline recommends use of antibiotics for patients with COPD exacerbations who have two of these three symptoms: increased dyspnea, increased sputum volume and increased sputum purulence. Routine use of sputum cultures in all patients is not recommended due to the long turnaround time and unreliable results. In COPD patients with frequent exacerbations or suspected resistant organisms, such as &lt;em&gt;Pseudomonas&lt;/em&gt;, it may be helpful to obtain a culture &lt;em&gt;[Guideline]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;Choice of antibiotic should be based on patient factors, including living situation (private residence, assisted living type setting, or long-term care), severity of illness and recent use of antibiotics. Also, local bacterial resistance patterns should be taken into consideration. The GOLD guideline recommends initial empirical treatment with an aminopenicillin with or without clavulanic acid, a macrolide or tetracycline. Fluoroquinolones also can be used in higher-risk patients, especially those over 65 years old and/or having more than three exacerbations per year &lt;em&gt;[Guideline]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;&lt;strong&gt;Oxygen Saturation/Arterial Blood Gas Measurement&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;        &lt;p&gt;Oxymetric evaluation of patients with COPD exacerbations is mandatory. Patients with oxygen saturations of 80% to 90% on room air can be titrated with supplemental oxygen to a saturation level of 90% with little concern of significant hypercarbia, unless such intervention results in somnolence. In such cases, or if the oxygen saturation is less than 80% upon presentation, an arterial blood gas should be obtained. If the pH is less than 7.32, admission to the hospital should be arranged because of the risk of acute respiratory failure. If outpatient management has been decided upon, the patient should be ambulated to determine what oxygen flow is needed to maintain oxygen saturations at 90% while walking &lt;em&gt;[Low Quality Evidence]&lt;/em&gt;.&lt;/p&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;10&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;strong&gt;Positive Response to Treatment?&lt;/strong&gt;&#xD;&#xA;        &lt;p&gt;The following criteria may be used as evidence of improvement in COPD exacerbation:&lt;/p&gt;&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Decreased work of breathing and improved oxygen exchange &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Decrease in cough, sputum production, fever, or dyspnea &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Decrease in respiratory rate &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Decrease in heart rate &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Decrease in accessory muscle use &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Increase in function and endurance &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;11&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;strong&gt;Arrange for Follow-Up&lt;/strong&gt;&#xD;&#xA;        &lt;p&gt;A follow-up appointment between the primary care clinician and the patient should occur within 1 to 4 weeks to reassess management strategies and supplemental oxygen needs.&lt;/p&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;ol style=&quot;list-style-type: decimal;&quot; start=&quot;12&quot;&gt;&#xD;&#xA;        &lt;li&gt;&lt;strong&gt;Admit to Hospital &amp;ndash; Out of Guideline&lt;/strong&gt;&#xD;&#xA;        &lt;p&gt;The following may be indications to consider hospital admission for an acute exacerbation of COPD:&lt;/p&gt;&#xD;&#xA;        &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;            &lt;li&gt;Marked increase in intensity of symptoms, such as sudden development of resting dyspnea &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;History of severe COPD, especially if mechanical ventilation was required &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Onset of new physical signs (e.g., cyanosis, peripheral edema) &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Failure of exacerbation to respond to initial outpatient medical management &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;High risk comorbidities, pulmonary (e.g., pneumonia requiring hospitalization) or cardiac symptoms &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Increasing hypoxemia despite supplemental oxygen &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;New or worsening carbon dioxide (CO&lt;sub&gt;2&lt;/sub&gt;) retention or pH less than 7.32 &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Marked decrease in ability to ambulate, eat, or sleep due to dyspnea &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;History of prolonged, progressive symptoms &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Newly occurring arrhythmias &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Diagnostic uncertainty &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Older age &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Insufficient home support &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Decrease in alertness &lt;/li&gt;&#xD;&#xA;            &lt;li&gt;Pulmonary embolism &lt;/li&gt;&#xD;&#xA;        &lt;/ul&gt;&#xD;&#xA;        &lt;p&gt;&lt;em&gt;[Guideline]&lt;/em&gt;, &lt;em&gt;[Systematic Review]&lt;/em&gt;&lt;/p&gt;&#xD;&#xA;        &lt;/li&gt;&#xD;&#xA;    &lt;/ol&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;&lt;span style=&quot;text-decoration: underline;&quot;&gt;Definitions&lt;/span&gt;&lt;/strong&gt;:&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;Following a review of several evidence rating and recommendation writing systems, Institute for Clinical System Improvement (ICSI) has made a decision to transition to the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Crosswalk between ICSI Evidence Grading System and GRADE&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;hr /&gt;&#xD;&#xA;    &lt;table border=&quot;0&quot; cellspacing=&quot;5&quot; cellpadding=&quot;9&quot; summary=&quot;Table: Crosswalk between ICSI Evidence Grading System and Grading of Recommendations Assessment, Development and Evaluation (GRADE)&quot;&gt;&#xD;&#xA;        &lt;thead&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot; scope=&quot;col&quot;&gt;ICSI GRADE System&lt;/th&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot; colspan=&quot;2&quot; scope=&quot;col&quot;&gt;Previous ICSI System&lt;/th&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/thead&gt;&#xD;&#xA;        &lt;tbody&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;&lt;strong&gt;High&lt;/strong&gt;, if no limitation&lt;/td&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot;&gt;Class A:&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Randomized, controlled trial&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot; rowspan=&quot;2&quot; scope=&quot;row&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot;&gt;Class B:&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;[observational]&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Cohort study&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot; rowspan=&quot;2&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot;&gt;Class C:&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;[observational]&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Non-randomized trial with concurrent or historical controls&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Case-control study&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Population-based descriptive study&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;*Low&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Study of sensitivity and specificity of a diagnostic test&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;*Following individual study review, may be elevated to Moderate or High depending upon study design&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot;&gt;Class D:&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;[observational]&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Cross-sectional study&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot; rowspan=&quot;2&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Case series&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Case report&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Meta-analysis&lt;/th&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot;&gt;Class M:&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Meta-analysis&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Systematic Review&lt;/th&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Systematic review&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Decision Analysis&lt;/th&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Decision analysis&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Cost-Effectiveness Analysis&lt;/th&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Cost-effectiveness analysis&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot;&gt;Class R:&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Consensus statement&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Consensus report&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot;&gt;&amp;nbsp;&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Narrative review&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Guideline&lt;/th&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot;&gt;Class R:&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Guideline&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot; colspan=&quot;3&quot; scope=&quot;row&quot;&gt;&amp;nbsp;&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;            &lt;tr&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot; scope=&quot;row&quot;&gt;Low&lt;/th&gt;&#xD;&#xA;                &lt;th valign=&quot;top&quot;&gt;Class X:&lt;/th&gt;&#xD;&#xA;                &lt;td valign=&quot;top&quot;&gt;Medical opinion&lt;/td&gt;&#xD;&#xA;            &lt;/tr&gt;&#xD;&#xA;        &lt;/tbody&gt;&#xD;&#xA;    &lt;/table&gt;&#xD;&#xA;    &lt;hr /&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Evidence Definitions&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;High Quality Evidence&lt;/strong&gt; = Further research is very unlikely to change confidence in the estimate of effect.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Moderate Quality Evidence&lt;/strong&gt; = Further research is likely to have an important impact on confidence in the estimate of effect and may change the estimate.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;&lt;strong&gt;Low Quality Evidence&lt;/strong&gt; = Further research is very likely to have an important impact on confidence in the estimate of effect and is likely to change the estimate or any estimate of effect is very uncertain.&lt;/p&gt;&#xD;&#xA;    &lt;p&gt;In addition to evidence that is graded and used to formulate recommendations, additional pieces of literature will be used to inform the reader of other topics of interest. This literature is not given an evidence grade and is instead identified as a &lt;strong&gt;Reference&lt;/strong&gt; throughout the document.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="138" OrdBy="515" ID="423" Name="Clinical Algorithm(s)" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;A detailed and annotated clinical algorithm is provided in the &lt;a href=&quot;https://www.icsi.org/_asset/yw83gh/COPD.pdf&quot; title=&quot;ICSI Web site&quot;&gt;original guideline document&lt;/a&gt; for diagnosis and management of chronic obstructive pulmonary disease.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="424" OrdBy="600" Name="Evidence Supporting the Recommendations"><Field FieldID="139" OrdBy="610" ID="426" Name="Type of Evidence Supporting the Recommendations" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The type of supporting evidence is classified for selected recommendations (see the &quot;Major Recommendations&quot; field).&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="427" OrdBy="700" Name="Benefits/Harms of Implementing the Guideline Recommendations"><Field FieldID="152" OrdBy="705" ID="428" Name="Potential Benefits" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Accurate diagnosis and appropriate management of chronic obstructive pulmonary disease&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="153" OrdBy="710" ID="429" Name="Potential Harms" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Adverse Effects of Medication&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Toxicities positively associated with higher serum concentration of theophylline include seizure and tachyarrhythmia. Other, more common adverse events occurring throughout the dosing range include headache, insomnia, nausea and heartburn. Theophylline is extensively hepatically metabolized; as a result, several drugs, cigarette smoking, and hepatic insufficiency in addition to cardiac decompensation and age may alter clearance. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Tremor can develop with high doses of albuterol. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Use of high dose inhaled steroids is not generally recommended, and a decision to use them needs to take into account the potential increased risk of pneumonia. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Given the toxicity of long-term treatment and the lack of prospective studies on the long-term effects, long-term treatment with oral glucocorticosteroids is not recommended in the management of stable chronic obstructive pulmonary disease (COPD). &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Noted side effects of roflumilast have included weight loss, nausea, diarrhea, and headache. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Due to the long-term side effects and potential colonization with macrolide resistant bacteria, azithromycin should not be initiated without a specialty consultation. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Concerns have been raised about the toxicity of freon. Dry powder inhalers have been developed as a response to concerns about freon toxicity. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Adverse Effects of Surgical Procedures&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Lung volume reduction surgery demonstrated increased mortality and no functional improvement for patients with non-upper lobe emphysema. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Perioperative mortality, rejection, bronchiolitis obliterans, cytomegalovirus, fungal and bacterial infections, and lymphoproliferative disease are associated with transplant surgery. Donor lung availability, high initial and ongoing immunosuppressive regimen costs are also factors that must be considered. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field></Section><Section SecID="430" OrdBy="800" Name="Contraindications"><Field FieldID="144" OrdBy="805" ID="431" Name="Contraindications" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;strong&gt;Relative Contraindications for Participation in Pulmonary Rehabilitation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Patients with conditions that might interfere with the patient undergoing a rehabilitation program (e.g., coronary artery disease, cognitive impairment interfering with learning, severe psychiatric disturbances) &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Patients with conditions that might place the patient at risk during exercise training; many patients with chronic obstructive pulmonary disease (COPD) are older with a history of cigarette smoking and are at risk for heart disease. Cardiac and pulmonary stress testing should be routinely performed to exclude silent cardiac disease and assure safety during exercise training. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Relative Contraindications for Lung Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Age limits:&#xD;&#xA;    &lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;        &lt;li&gt;Heart-lung transplants: ~55 years &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Double lung transplant: ~60 years &lt;/li&gt;&#xD;&#xA;        &lt;li&gt;Single lung transplant: ~65 years &lt;/li&gt;&#xD;&#xA;    &lt;/ul&gt;&#xD;&#xA;    &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Symptomatic osteoporosis &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Oral corticosteroids greater than 20 mg/day &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Psychosocial problems &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Requirement for invasive mechanical ventilation &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Human immunodeficiency virus (HIV) infection &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Absolute Contraindications for Lung Transplantation&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Severe musculoskeletal disease affecting the thorax &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Substance addiction within previous 6 months &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Dysfunction of extrathoracic organ, particularly renal dysfunction &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Active malignancy within 2 years except basal or squamous cell carcinoma of skin &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hepatitis B antigen positive &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hepatitis C with biopsy-proven evidence of liver disease &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Contraindications to Medications&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The use of &lt;em&gt;roflumilast&lt;/em&gt; is contraindicated in patients with moderate to severe hepatic impairment.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="432" OrdBy="900" Name="Qualifying Statements"><Field FieldID="137" OrdBy="905" ID="433" Name="Qualifying Statements" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The information contained in this Institute for Clinical Systems Improvement (ICSI) Health Care Guideline is intended primarily for health professionals and other expert audiences. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;This ICSI Health Care Guideline should not be construed as medical advice or medical opinion related to any specific facts or circumstances. Patients are urged to consult a health care professional regarding their own situation and any specific medical questions they may have. In addition, they should seek assistance from a health care professional in interpreting this ICSI Health Care Guideline and applying it in their individual case. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;This ICSI Health Care Guideline is designed to assist clinicians by providing an analytical framework for the valuation and treatment of patients, and is not intended either to replace a clinician's judgment or to establish a protocol for all patients with a particular condition. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field></Section><Section SecID="434" OrdBy="1000" Name="Implementation of the Guideline"><Field FieldID="131" OrdBy="1010" ID="436" Name="Description of Implementation Strategy" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Once a guideline is approved for general implementation, a medical group can choose to concentrate on the implementation of that guideline. When four or more groups choose the same guideline to implement and they wish to collaborate with others, they may form an action group.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In the action group, each medical group sets specific goals they plan to achieve in improving patient care based on the particular guideline(s). Each medical group shares its experiences and supporting measurement results within the action group. This sharing facilitates a collaborative learning environment. Action group learnings are also documented and shared with interested medical groups within the collaborative.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Currently, action groups may focus on one guideline or a set of guidelines such as hypertension, lipid treatment, and tobacco cessation.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Detailed measurement strategies are presented in the original guideline document to help close the gap between clinical practice and the guideline recommendations. Summaries of the measures are provided in the National Quality Measures Clearinghouse (NQMC).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Implementation Recommendations&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Prior to implementation, it is important to consider current organizational infrastructure that address the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;System and process design &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Training and education &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Culture and the need to shift values, beliefs and behaviors of the organization &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;The following system changes were identified by the guideline work group as key strategies for health care systems to incorporate in support of the implementation of this guideline.&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;A model of patient education should be established in the clinics based upon individual learning needs assessments and including coordinated plans jointly developed by educators, patients, and their families. Patient education should include core learning and needs objectives based upon individual needs. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Establish tobacco status at each visit. Advise to quit and provide supportive interventions including pharmacotherapy if appropriate. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="117" OrdBy="1015" ID="437" Name="Implementation Tools" Type="picklist-many"><FieldValue Value="Clinical Algorithm" /><FieldValue Value="Quality Measures" /><FieldValue Value="Quick Reference Guides/Physician Guides" /><FieldValue Value="Resources" /></Field><Field FieldID="102" OrdBy="1020" ID="438" Name="Related NQMC Measures" Type="xref"><FieldValue Value="&lt;a href=&quot;http://www.qualitymeasures.ahrq.gov/content.aspx?id=44973&quot; target=&quot;_blank&quot;&gt;Diagnosis and management of chronic obstructive pulmonary disease (COPD): percentage of patients with a diagnosis of COPD who had spirometry testing to establish COPD diagnosis.&lt;/a&gt;" /><FieldValue Value="&lt;a href=&quot;http://www.qualitymeasures.ahrq.gov/content.aspx?id=44974&quot; target=&quot;_blank&quot;&gt;Diagnosis and management of chronic obstructive pulmonary disease (COPD): percentage of patients with COPD who are asked about smoking and smoking exposure at every visit with clinician.&lt;/a&gt;" /><FieldValue Value="&lt;a href=&quot;http://www.qualitymeasures.ahrq.gov/content.aspx?id=44975&quot; target=&quot;_blank&quot;&gt;Diagnosis and management of chronic obstructive pulmonary disease (COPD): percentage of patients with COPD who are smokers who have assessment of readiness to attempt smoking cessation.&lt;/a&gt;" /><FieldValue Value="&lt;a href=&quot;http://www.qualitymeasures.ahrq.gov/content.aspx?id=44976&quot; target=&quot;_blank&quot;&gt;Diagnosis and management of chronic obstructive pulmonary disease (COPD): percentage of COPD patients who are smokers who receive a smoking cessation intervention.&lt;/a&gt;" /><FieldValue Value="&lt;a href=&quot;http://www.qualitymeasures.ahrq.gov/content.aspx?id=44977&quot; target=&quot;_blank&quot;&gt;Diagnosis and management of chronic obstructive pulmonary disease (COPD): percentage of patients with COPD and smokers who quit smoking (100% quit-rate goal).&lt;/a&gt;" /><FieldValue Value="&lt;a href=&quot;http://www.qualitymeasures.ahrq.gov/content.aspx?id=44978&quot; target=&quot;_blank&quot;&gt;Diagnosis and management of chronic obstructive pulmonary disease (COPD): percentage of patients with COPD who are prescribed appropriate therapy.&lt;/a&gt;" /><FieldValue Value="&lt;a href=&quot;http://www.qualitymeasures.ahrq.gov/content.aspx?id=44979&quot; target=&quot;_blank&quot;&gt;Diagnosis and management of chronic obstructive pulmonary disease (COPD): percentage of COPD patients seen in emergency room for COPD-related exacerbations in one month.&lt;/a&gt;" /><FieldValue Value="&lt;a href=&quot;http://www.qualitymeasures.ahrq.gov/content.aspx?id=44980&quot; target=&quot;_blank&quot;&gt;Diagnosis and management of chronic obstructive pulmonary disease (COPD): percentage of COPD patients who require hospital admission for COPD-related exacerbations in one month.&lt;/a&gt;" /><FieldValue Value="&lt;a href=&quot;http://www.qualitymeasures.ahrq.gov/content.aspx?id=44981&quot; target=&quot;_blank&quot;&gt;Diagnosis and management of chronic obstructive pulmonary disease (COPD): percentage of COPD patients with two or more hospitalizations over a 12-month period.&lt;/a&gt;" /><FieldValue Value="&lt;a href=&quot;http://www.qualitymeasures.ahrq.gov/content.aspx?id=44982&quot; target=&quot;_blank&quot;&gt;Diagnosis and management of chronic obstructive pulmonary disease (COPD): percentage of patients with moderate or severe COPD who have been referred to a pulmonary rehabilitation or exercise program.&lt;/a&gt;" /><FieldValue Value="&lt;a href=&quot;http://www.qualitymeasures.ahrq.gov/content.aspx?id=44983&quot; target=&quot;_blank&quot;&gt;Diagnosis and management of chronic obstructive pulmonary disease (COPD): percentage of patients with COPD who have discussed advance care planning, including health care directives (or advanced directives) and goals of care with their health care professional.&lt;/a&gt;" /></Field></Section><Section SecID="439" OrdBy="1100" Name="Institute of Medicine (IOM) National Healthcare Quality Report Categories"><Field FieldID="50" OrdBy="1105" ID="440" Name="IOM Care Need" Type="picklist-many"><FieldValue Value="End of Life Care" /><FieldValue Value="Getting Better" /><FieldValue Value="Living with Illness" /></Field><Field FieldID="51" OrdBy="1110" ID="441" Name="IOM Domain" Type="picklist-many"><FieldValue Value="Effectiveness" /><FieldValue Value="Patient-centeredness" /></Field></Section><Section SecID="442" OrdBy="1200" Name="Identifying Information and Availability"><Field FieldID="97" OrdBy="1201" ID="392" Name="Bibliographic Source(s)" Type="citation"><FieldValue Value="&lt;table&gt;&lt;tr&gt;&lt;td&gt;Anderson B, Conner K, Dunn C, Kerestes G, Lim K, Myers C, Olson J, Raikar S, Schultz H, Setterlund L. Diagnosis and management of chronic obstructive pulmonary disease (COPD). Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2013 Mar. 68 p.  [81 references]&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;" /></Field><Field FieldID="124" OrdBy="1205" ID="443" Name="Adaptation" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Not applicable: The guideline was not adapted from another source.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="128" OrdBy="1215" ID="445" Name="Date Released" Type="text"><FieldValue Value="2001 Dec (revised 2013 Mar)" /></Field><Field FieldID="158" OrdBy="1225" ID="447" Name="Guideline Developer(s)" Type="orglist-p"><FieldValue Value="Institute for Clinical Systems Improvement - Nonprofit Organization" /></Field><Field FieldID="123" OrdBy="1230" ID="448" Name="Guideline Developer Comment" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Institute for Clinical Systems Improvement (ICSI) comprises 50+ medical group and hospital members representing 9,000 physicians in Minnesota and surrounding areas, and is sponsored by five nonprofit health plans. For a list of sponsors and participating organizations, see the &lt;a href=&quot;https://www.icsi.org/about_icsi/members__sponsors/&quot; title=&quot;ICSI Web site&quot;&gt;ICSI Web site&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="125" OrdBy="1235" ID="449" Name="Source(s) of Funding" Type="text"><FieldValue Value="&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;The Institute for Clinical Systems Improvement (ICSI) provided the funding for this guideline. The annual dues of the member medical groups and sponsoring health plans fund ICSI's work. Individuals on the work group are not paid by ICSI, but are supported by their medical group for this work. &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;ICSI facilitates and coordinates the guideline development and revision process. ICSI, member medical groups, and sponsoring health plans review and provide feedback, but do not have editorial control over the work group. All recommendations are based on the work group's independent evaluation of the evidence. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;" /></Field><Field FieldID="126" OrdBy="1240" ID="450" Name="Guideline Committee" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Chronic Obstructive Pulmonary Disease (COPD) Work Group&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="127" OrdBy="1245" ID="451" Name="Composition of Group That Authored the Guideline" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;&lt;em&gt;Work Group Members&lt;/em&gt;: Blair Anderson (&lt;em&gt;Work Group Leader&lt;/em&gt;) (HealthPartners Medical Group and Regions Hospital) (Pulmonology); G. Paul Kerestes, MD (Allina Medical Clinic) (Family Medicine); Christina Dunn, MD (Fairview Health Services) (Internal Medicine); Jennifer Olson, CRT, RRT (Fairview Health Services) (Nursing and Health Education); Heidi Schultz, PharmD (Fairview Health Services) (Pharmacy); Shama Raikar, MD (HealthPartners Medical Group and Regions Hospital) (Internal Medicine); Kaiser Lim, MD (Mayo Clinic) (Pulmonary and Critical Care Medicine); Kristen Conner, BSN, MSN (North Memorial Health Care) (Nursing and Health Education); Cassandra Myers (Institute for Clinical Systems Improvement [ICSI]) (Clinical Systems Improvement Facilitator); Linda Setterlund (ICSI) (Clinical Systems Improvement Facilitator)&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="147" OrdBy="1250" ID="452" Name="Financial Disclosures/Conflicts of Interest" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The Institute for Clinical Systems Improvement (ICSI) has long had a policy of transparency in declaring potential conflicting and competing interests of all individuals who participate in the development, revision and approval of ICSI guidelines and protocols.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In 2010, the ICSI Conflict of Interest Review Committee was established by the Board of Directors to review all disclosures and make recommendations to the board when steps should be taken to mitigate potential conflicts of interest, including recommendations regarding removal of work group members. This committee has adopted the Institute of Medicine Conflict of Interest standards as outlined in the report Clinical Practice Guidelines We Can Trust (2011).&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Where there are work group members with identified potential conflicts, these are disclosed and discussed at the initial work group meeting. These members are expected to recuse themselves from related discussions or authorship of related recommendations, as directed by the Conflict of Interest committee or requested by the work group.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The complete ICSI policy regarding Conflicts of Interest is available at the &lt;a href=&quot;https://www.icsi.org/_asset/fwsfmi/coi_policyletter.pdf&quot; title=&quot;ICSI Web site&quot;&gt;ICSI Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Disclosure of Potential Conflicts of Interest&lt;/strong&gt;&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Blair M. Anderson, MD (Work Group Leader)&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Physician, Pulmonology, HealthPartners Medical Group and Regions Hospital&lt;br /&gt;&#xD;&#xA;National, Regional, Local Committee Affiliations: None&lt;br /&gt;&#xD;&#xA;Guideline Related Activities: None&lt;br /&gt;&#xD;&#xA;Research Grants: None&lt;br /&gt;&#xD;&#xA;Financial/Non-Financial Conflicts of Interest: None&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Kristen K. Conner, BSN, MSN (Work Group Member)&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Nurse Practitioner, North Memorial Health Care&lt;br /&gt;&#xD;&#xA;National, Regional, Local Committee Affiliations: None&lt;br /&gt;&#xD;&#xA;Guideline Related Activities: None&lt;br /&gt;&#xD;&#xA;Research Grants: None&lt;br /&gt;&#xD;&#xA;Financial/Non-Financial Conflicts of Interest: None&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Christina T. Dunn, MD (Work Group Member)&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Physician, Internal Medicine, Fairview Health Services&lt;br /&gt;&#xD;&#xA;National, Regional, Local Committee Affiliations: None&lt;br /&gt;&#xD;&#xA;Guideline Related Activities: None&lt;br /&gt;&#xD;&#xA;Research Grants: None&lt;br /&gt;&#xD;&#xA;Financial/Non-Financial Conflicts of Interest: None&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;G. Paul Kerestes, MD (Work Group Member)&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Physician, Family Medicine, Allina Medical Clinic&lt;br /&gt;&#xD;&#xA;National, Regional, Local Committee Affiliations: None&lt;br /&gt;&#xD;&#xA;Guideline Related Activities: None&lt;br /&gt;&#xD;&#xA;Research Grants: None&lt;br /&gt;&#xD;&#xA;Financial/Non-Financial Conflicts of Interest: None&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Kaiser G. Lim, MD (Work Group Member)&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Physician, Pulmonology, Mayo Clinic&lt;br /&gt;&#xD;&#xA;National, Regional, Local Committee Affiliations: None&lt;br /&gt;&#xD;&#xA;Guideline Related Activities: ICSI Venous Thromboembolism Diagnosis and Treatment Guideline Work Group&lt;br /&gt;&#xD;&#xA;Research Grants: None&lt;br /&gt;&#xD;&#xA;Financial/Non-Financial Conflicts of Interest: None&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Jennifer L. Olson, CRT, RRT (Work Group Member)&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Respiratory Therapist, Fairview Health Services&lt;br /&gt;&#xD;&#xA;National, Regional, Local Committee Affiliations: None&lt;br /&gt;&#xD;&#xA;Guideline Related Activities: None&lt;br /&gt;&#xD;&#xA;Research Grants: None&lt;br /&gt;&#xD;&#xA;Financial/Non-Financial Conflicts of Interest: None&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Shama H. Raikar, MD (Work Group Member)&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Physician, Internal Medicine, HealthPartners Medical Group and Regions Hospital&lt;br /&gt;&#xD;&#xA;National, Regional, Local Committee Affiliations: None&lt;br /&gt;&#xD;&#xA;Guideline Related Activities: ICSI Heart Failure in Adults Guideline Work Group&lt;br /&gt;&#xD;&#xA;Research Grants: None&lt;br /&gt;&#xD;&#xA;Financial/Non-Financial Conflicts of Interest: None&lt;/p&gt;&#xD;&#xA;&lt;p&gt;&lt;strong&gt;Heidi E. Schultz, PharmD (Work Group Member)&lt;/strong&gt;&lt;br /&gt;&#xD;&#xA;Pharmacist, Fairview Health Services&lt;br /&gt;&#xD;&#xA;National, Regional, Local Committee Affiliations: None&lt;br /&gt;&#xD;&#xA;Guideline Related Activities: None&lt;br /&gt;&#xD;&#xA;Research Grants: None&lt;br /&gt;&#xD;&#xA;Financial/Non-Financial Conflicts of Interest: None&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="120" OrdBy="1256" ID="393" Name="Guideline Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This is the current release of the guideline.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;This guideline updates a previous version: Institute for Clinical Systems Improvement (ICSI). Diagnosis and management of chronic obstructive pulmonary disease (COPD). Bloomington (MN): Institute for Clinical Systems Improvement (ICSI); 2011 Mar. 63 p.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="118" OrdBy="1260" ID="454" Name="Guideline Availability" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;Electronic copies: Available from the &lt;a href=&quot;https://www.icsi.org/guidelines__more/catalog_guidelines_and_more/catalog_guidelines/catalog_respiratory_guidelines/copd/&quot; title=&quot;ICSI Web site&quot;&gt;Institute for Clinical Systems Improvement (ICSI) Web site&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from ICSI, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; telephone, (952) 814-7060; fax, (952) 858-9675; Web site: &lt;a href=&quot;http://www.icsi.org&quot; title=&quot;ICSI Web site&quot;&gt;www.icsi.org&lt;/a&gt;; e-mail: &lt;a href=&quot;mailto:icsi.info@icsi.org&quot;&gt;icsi.info@icsi.org&lt;/a&gt;.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="119" OrdBy="1265" ID="455" Name="Availability of Companion Documents" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;The following is available:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Diagnosis and management of chronic obstructive pulmonary disease (COPD). Executive summary. Bloomington (MN): Institute for Clinical Systems Improvement; 2013 Mar. 1 p. Electronic copies: Available in Portable Document Format (PDF) from the &lt;a href=&quot;https://www.icsi.org/_asset/0zmp7n/COPDES.pdf&quot; title=&quot;ICSI Web site&quot;&gt;Institute for Clinical Systems Improvement (ICSI) Web site&lt;/a&gt;. &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&#xD;&#xA;&lt;p&gt;Print copies: Available from ICSI, 8009 34th Avenue South, Suite 1200, Bloomington, MN 55425; telephone, (952) 814-7060; fax, (952) 858-9675; Web site: &lt;a href=&quot;http://www.icsi.org&quot; title=&quot;ICSI Web site&quot;&gt;www.icsi.org&lt;/a&gt;; e-mail: &lt;a href=&quot;mailto:icsi.info@icsi.org&quot;&gt;icsi.info@icsi.org&lt;/a&gt;.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;In addition, the appendices to the &lt;a href=&quot;https://www.icsi.org/_asset/yw83gh/COPD.pdf&quot; title=&quot;ICSI Web site&quot;&gt;original guideline document&lt;/a&gt; contain the following:&lt;/p&gt;&#xD;&#xA;&lt;ul style=&quot;list-style-type: disc;&quot;&gt;&#xD;&#xA;    &lt;li&gt;Estimated comparative daily dosage for inhaled corticosteroids &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Hydrofluoro-alkane directory &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Medicare standards for oxygen coverage &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;Summary of structure and services - pulmonary rehabilitation program &lt;/li&gt;&#xD;&#xA;    &lt;li&gt;The shared decision making model &lt;/li&gt;&#xD;&#xA;&lt;/ul&gt;&lt;/div&gt;" /></Field><Field FieldID="143" OrdBy="1275" ID="457" Name="Patient Resources" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;None available&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="142" OrdBy="1280" ID="458" Name="NGC Status" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary was completed by ECRI on August 26, 2002. The information was verified by the guideline developer on September 23, 2002. This summary was updated by ECRI on July 12, 2004, and most recently on February 17, 2005. This summary was updated by ECRI on December 5, 2005 following the U.S. Food and Drug Administration (FDA) advisory on long-acting beta2-adrenergic agonists (LABA). This NGC summary was updated by ECRI on January 16, 2006. This summary was updated by ECRI on November 21, 2006 following the FDA advisory on Tamiflu. This NGC summary was updated by ECRI on April 4, 2007. This summary was updated by ECRI Institute on March 10, 2008 following the U.S. Food and Drug Administration (FDA) advisory on Tamiflu (oseltamivir phosphate). This summary was updated by ECRI Institute on April 9, 2008 following the U.S. Food and Drug Administration (FDA) advisory on Relenza (zanamivir). This summary was updated by ECRI Institute on September 16, 2009, June 28, 2011, and June 10, 2013. This summary was updated by ECRI Institute on October 25, 2013 following the U.S. Food and Drug Administration advisory on Fluoroquinolone Antibacterial Drugs.&lt;/p&gt;&lt;/div&gt;" /></Field><Field FieldID="141" OrdBy="1290" ID="460" Name="Copyright Statement" Type="text"><FieldValue Value="&lt;div class=&quot;content_para&quot;&gt;&lt;p&gt;This NGC summary (abstracted Institute for Clinical Systems Improvement [ICSI] Guideline) is based on the original guideline, which is subject to the guideline developer's copyright restrictions.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;The abstracted ICSI Guidelines contained in this Web site may be downloaded by any individual or organization. If the abstracted ICSI Guidelines are downloaded by an individual, the individual may not distribute copies to third parties.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;If the abstracted ICSI Guidelines are downloaded by an organization, copies may be distributed to the organization's employees but may not be distributed outside of the organization without the prior written consent of the Institute for Clinical Systems Improvement, Inc.&lt;/p&gt;&#xD;&#xA;&lt;p&gt;All other copyright rights in the abstracted ICSI Guidelines are reserved by the Institute for Clinical Systems Improvement, Inc. The Institute for Clinical Systems Improvement, Inc. assumes no liability for any adaptations or revisions or modifications made to the abstracts of the ICSI Guidelines.&lt;/p&gt;&lt;/div&gt;" /></Field></Section><Section SecID="99999" OrdBy="99999" Name="Disclaimer"><Field FieldID="99999" OrdBy="99999" ID="99999" Name="NGC Disclaimer" Type="text"><FieldValue Value="&lt;p&gt;The National Guideline Clearinghouse™ (NGC) does not develop, produce, approve, or endorse the guidelines represented on this site.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;All guidelines summarized by NGC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public or private organizations, other government agencies, health care organizations or plans, and similar entities.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Guidelines represented on the NGC Web site are submitted by guideline developers, and are screened solely to determine that they meet the NGC Inclusion Criteria which may be found at &lt;a href=&quot;/about/inclusion-criteria.aspx&quot;&gt;http://www.guideline.gov/about/inclusion-criteria.aspx&lt;/a&gt;.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;NGC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or clinical efficacy or effectiveness of the clinical practice guidelines and related materials represented on this site. Moreover, the views and opinions of developers or authors of guidelines represented on this site do not necessarily state or reflect those of NGC, AHRQ, or its contractor ECRI Institute, and inclusion or hosting of guidelines in NGC may not be used for advertising or commercial endorsement purposes.&lt;/p&gt; &#xD;&#xA;&lt;p&gt;Readers with questions regarding guideline content are directed to contact the guideline developer.&lt;/p&gt;" /></Field></Section></Version>
